



## Youn H Kim, MD

The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)

Dermatology

 NIH Biosketch available Online

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr

Clinic A MC 6560

Stanford, CA 94305

**Tel** (650) 498-6000      **Fax** (650) 721-2521

### Bio

---

#### BIO

Youn H. Kim, M.D., is a Professor of Dermatology and member of the Stanford Cancer Institute. She is the Director of Stanford's Multidisciplinary Cutaneous Lymphoma Clinic/Program (MCLP). Her current research is dedicated towards strengthening the collaborative interface for novel discoveries and exploring new and improved therapies with tumor-specific targets and enhanced synergy and/or potency. She and her multidisciplinary colleagues are exploring novel immune/cell therapy modalities including in situ vaccination, immune checkpoint blockades, and unique allogeneic HSCT strategies.

#### CLINICAL FOCUS

- Cancer > Cutaneous (Dermatologic) Oncology
- Cutaneous Lymphoma
- Cutaneous Lymphoma - Dermatology
- Dermatology
- Mycosis Fungoides
- Mycosis Fungoides - Dermatology
- Skin Cancer

#### ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Dermatology
- Professor - University Medical Line (By courtesy), Medicine - Oncology
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Director, Multi-disciplinary Cutaneous Lymphoma Program, Stanford University Medical Center, (2004- present)

#### HONORS AND AWARDS

- The Best Doctors in America: Pacific Region, Woodward/White, Inc (1996-)

- Distinguished Service Award, Department of Dermatology, Stanford University School of Medicine (1995)
- Alwin C. Rambar-James B.D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2001)

## PROFESSIONAL EDUCATION

- Medical Education: Stanford University School of Medicine (1984) CA
- Internship: Kaiser Permanente San Francisco Internal Medicine Residency (1985) CA
- Residency: Stanford University Dermatology Residency (1989) CA
- Board Certification: Dermatology, American Board of Dermatology (1989)
- Doctor of Medicine, Stanford University , Medicine (1984)
- Bachelor of Arts, Wellesley College , Chemistry (1980)

## LINKS

- Cutaneous Lymphoma: <http://cutaneouslymphoma.stanford.edu>
- Video Story: <https://stanfordhealthcare.org/stanford-health-care-now/why-i-got-into-medicine/why-medicine-youn-kim-md.html>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.

### CLINICAL TRIALS

- A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas, Recruiting
- Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing, Recruiting
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients, Recruiting
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome, Recruiting
- Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome, Recruiting
- A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma, Not Recruiting
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study), Not Recruiting
- A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma, Not Recruiting
- A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers, Not Recruiting
- A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Not Recruiting
- A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Not Recruiting
- A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma, Not Recruiting
- A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001, Not Recruiting
- A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma, Not Recruiting
- A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors, Not Recruiting
- An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides, Not Recruiting
- Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level, Not Recruiting
- Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma, Not Recruiting
- Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001, Not Recruiting

- FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides), Not Recruiting
- Forodesine in the Treatment of Cutaneous T-Cell Lymphoma, Not Recruiting
- IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma, Not Recruiting
- Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome, Not Recruiting
- Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides, Not Recruiting
- Mogamulizumab Q4week Dosing in Participants With R/R CTCL, Not Recruiting
- Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL, Not Recruiting
- NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT), Not Recruiting
- Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome, Not Recruiting
- Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody, Not Recruiting
- Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL, Not Recruiting
- Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A, Not Recruiting
- Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma, Not Recruiting
- Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides, Not Recruiting
- Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma, Not Recruiting
- Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL), Not Recruiting
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL, Not Recruiting
- Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome, Not Recruiting
- Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL), Not Recruiting
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL, Not Recruiting
- Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL), Not Recruiting
- Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma, Not Recruiting
- Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Not Recruiting
- Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma, Not Recruiting
- Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma, Not Recruiting
- Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas, Not Recruiting
- Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma, Not Specified

## Teaching

---

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Dermatology (Fellowship Program)

## Publications

---

### PUBLICATIONS

- **Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma**  
Bojanini, L., Herrera, M., Li, S., Bandali, T., Xu, N. Y., Ahmed, A. A., Khodadoust, M. S., Kim, Y. H.  
ELSEVIER.2024: 1677-1678
- **Genetic alteration of class I HLA in cutaneous T-cell lymphoma.** *Blood*

- Kwang, A. C., Duran, G. E., Fernandez-Pol, S., Najidh, S., Li, S., Bastidas Torres, A. N., Wang, E. B., Herrera, M., Bandali, T. I., Kurtz, D. M., Kim, Y. H., Khodadoust, M. S.  
2024
- **Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma.** *Blood neoplasia*  
Weng, W. K., Iragavarapu, C., Weng, G. M., Hoppe, R. T., Hiniker, S., Khodadoust, M. S., Kim, Y. H.  
2024; 1 (2): 100007
  - **Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.** *American journal of hematology*  
Mou, E., Fernandez-Pol, S., Li, S., Rieger, K. E., Novoa, R., Suarez, C. J., Wieland, R., Weng, W., Kim, Y. H., Khodadoust, M. S.  
2024
  - **What we have learnt about the treatment of advanced stage MF from the PROCLIFI study**  
Kim, Y. H., Quaglino, P., Scarisbrick, J.  
ELSEVIER SCI LTD.2023: S49-S50
  - **Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma**  
Kwang, A., Duran, G., Fernandez-Pol, S., Li, S., Najidh, S., Torres, A., Herrera, M., Wang, E., Kurtz, D., Kim, Y. H., Khodadoust, M.  
ELSEVIER SCI LTD.2023: S14
  - **Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome.** *Blood*  
Khodadoust, M. S., Mou, E., Kim, Y. H.  
2022
  - **Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.** *Oncoimmunology*  
Su, T., Duran, G. E., Kwang, A. C., Ramchurren, N., Fling, S. P., Kim, Y. H., Khodadoust, M. S.  
2022; 11 (1): 2115197
  - **Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.** *Dermatologic therapy*  
Bagot, M., Dalle, S., Sokol, L., Tsianakas, A., Musiek, A., Ortiz-Romero, P. L., Poligone, B., Duvic, M., Elmets, C., Leoni, M., Dwyer, K., Ito, T., Herr, et al  
2022: e15634
  - **Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.** *Blood*  
Beygi, S., Duran, G. E., Fernandez-Pol, S., Rook, A. H., Kim, Y. H., Khodadoust, M. S.  
2022
  - **Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial**  
Musiek, A., Whittaker, S., Horwitz, S., Bagot, M., Huen, A., Fisher, D., Haun, P., Vermeer, M., Ito, T., Dwyer, K., Medley, M., Kim, Y.  
WILEY.2022: 192-193
  - **Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.** *Blood*  
Olsen, E. A., Whittaker, S., Willemze, R., Pinter-Brown, L., Foss, F. M., Geskin, L. J., Schwartz, L. H., Horwitz, S. M., Guitart, J., Zic, J., Kim, Y. H., Wood, G. S., Duvic, et al  
2021
  - **Cutaneous T cell lymphoma.** *Nature reviews. Disease primers*  
Dummer, R., Vermeer, M. H., Scarisbrick, J. J., Kim, Y. H., Stonesifer, C., Tensen, C. P., Geskin, L. J., Quaglino, P., Ramelyte, E.  
2021; 7 (1): 61
  - **Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging** *FRONTIERS IN IMMUNOLOGY*  
Phillips, D., Schuerch, C. M., Khodadoust, M. S., Kim, Y. H., Nolan, G. P., Jiang, S.  
2021; 12: 687673
  - **Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome.** *Advances in radiation oncology*  
Fong, S., Hong, E. K., Khodadoust, M. S., Li, S., Hoppe, R. T., Kim, Y. H., Hiniker, S. M.  
2021; 6 (3): 100629

- **Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome.** *JAMA dermatology*  
Hirotsu, K. E., Neal, T. M., Khodadoust, M. S., Wang, J. Y., Rieger, K. E., Strelo, J., Hong, E., Kim, Y. H., Kwong, B. Y.  
2021
- **Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.** *European journal of cancer (Oxford, England : 1990)*  
Kim, Y. H., Prince, H. M., Whittaker, S., Horwitz, S. M., Duvic, M., Bechter, O., Sanches, J. A., Stadler, R., Scarisbrick, J., Quagliano, P., Zinzani, P. L., Wolter, P., Eradat, et al  
2021; 148: 411–21
- **Pembrolizumab in mycosis fungoides with PD-L1 structural variants.** *Blood advances*  
Beygi, S. n., Fernandez-Pol, S. n., Duran, G. n., Wang, E. B., Stehr, H. n., Zehnder, J. L., Ramchurren, N. n., Fling, S. P., Cheever, M. A., Weng, W. K., Kim, Y. H., Khodadoust, M. S.  
2021; 5 (3): 771–74
- **Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.** *Nature communications*  
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., Ramchurren, N., Cheever, M. A., Goltsev, et al  
2021; 12 (1): 6726
- **Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports.** *Diagnostic pathology*  
Rojansky, R., Fernandez-Pol, S., Wang, E., Rieger, K. E., Novoa, R. A., Zehnder, J. L., Kunder, C. A., Kim, Y. H., Khodadoust, M. S., Brown, R. A.  
2020; 15 (1): 122
- **Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma**  
Schurch, C. M., Phillips, D. J., Gutierrez, B., Matusiak, M., Bhate, S. S., Barlow, G. L., Fling, S. P., Ramchurren, N., Pierce, R. H., Cheever, M. A., Khodadoust, M. S., West, R., Kim, et al  
AMER ASSOC CANCER RESEARCH.2020
- **A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival.** *The American Journal of dermatopathology*  
Hoffmann, J. C., Atwater, S. K., Hong, E. n., Kumar, J. n., Khodadoust, M. n., Kim, Y. n., Ohgami, R. S.  
2020; 42 (6): 389–96
- **Histopathologic Characterization of Mogamulizumab-associated Rash.** *The American journal of surgical pathology*  
Wang, J. Y., Hirotsu, K. E., Neal, T. M., Raghavan, S. S., Kwong, B. Y., Khodadoust, M. S., Brown, R. A., Novoa, R. A., Kim, Y. H., Rieger, K. E.  
2020
- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*  
Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al  
2020; 4 (18): 4474–82
- **IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.** *The Lancet. Oncology*  
Bagot, M., Porcu, P., Marie-Cardine, A., Battistella, M., William, B. M., Vermeer, M., Whittaker, S., Rotolo, F., Ram-Wolff, C., Khodadoust, M. S., Bensussan, A., Paturel, C., Bonnafous, et al  
2019
- **Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs.** *Practical radiation oncology*  
Obeid, J., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., Kim, Y. H., Weng, W., Hoppe, R. T., Hiniker, S. M.  
2019
- **Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Khodadoust, M. S., Rook, A. H., Porcu, P. n., Foss, F. n., Moskowicz, A. J., Shustov, A. n., Shanbhag, S. n., Sokol, L. n., Fling, S. P., Ramchurren, N. n., Pierce, R. n., Davis, A. n., Shine, et al  
2019: JCO1901056

- **Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial** *LANCET ONCOLOGY*  
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P., Sokol, L., Morris, S., Kim, et al  
2018; 19 (9): 1192–1204
- **Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.** *The Lancet. Oncology*  
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., Sokol, L., Morris, S., Kim, et al  
2018
- **TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma**  
Faustman, D. L., Torrey, H., Khodadoust, M., Defusco, A., Baum, D., Rahbar, Z., Kim, Y. H.  
AMER ASSOC CANCER RESEARCH.2018
- **The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sezary Syndrome A Multi-institutional and International Pathology Study** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*  
Gru, A. A., Kim, J., Pulitzer, M., Guitart, J., Battistella, M., Wood, G. S., Cerroni, L., Kempf, W., Willemze, R., Pawade, J., Querfeld, C., Schaffer, A., Pincus, et al  
2018; 42 (6): 726–34
- **Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*  
Rahbar, Z., Li, S., Tavallaee, M., Novoa, R. A., Kim, J., Kim, Y. H.  
2018; 138 (5): 1204–6
- **Transcript-indexed ATAC-seq for precision immune profiling.** *Nature medicine*  
Satpathy, A. T., Saligrama, N. n., Buenrostro, J. D., Wei, Y. n., Wu, B. n., Rubin, A. J., Granja, J. M., Lareau, C. A., Li, R. n., Qi, Y. n., Parker, K. R., Mumbach, M. R., Serratelli, et al  
2018
- **Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies**  
Torrey, H., Defusco, A., Baum, D., Rahbar, Z., Khodadoust, M., Kim, Y. H., Faustman, D.  
BMC.2017
- **Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial** *LANCET*  
Prince, H., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., Akilov, O. E., Geskin, L., Trotman, et al  
2017; 390 (10094): 555–66
- **Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas** *MODERN PATHOLOGY*  
Guitart, J., Martinez-Escala, M., Subtil, A., Duvic, M., Pulitzer, M. P., Olsen, E. A., Kim, E., Rook, A. H., Samimi, S. S., Wood, G. S., Girardi, M., Junkins-Hopkins, J., Ivan, et al  
2017; 30 (5): 761–72
- **Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.** *Cancer cell*  
Qu, K. n., Zaba, L. C., Satpathy, A. T., Giresi, P. G., Li, R. n., Jin, Y. n., Armstrong, R. n., Jin, C. n., Schmitt, N. n., Rahbar, Z. n., Ueno, H. n., Greenleaf, W. J., Kim, et al  
2017
- **A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)**  
Kim, Y. H., Hoppe, R. T., Rook, A. H., Maity, A., Geskin, L. J., Horowitz, D. P., Finnegan, G., Khodadoust, M., Weng, W., Lares, A., Hong, E., Buchanan, M., Ma, et al  
AMER SOC HEMATOLOGY.2016
- **Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study**

- Khodadoust, M., Rook, A. H., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., Shanbhag, S., Sokol, L., Shine, R., Fling, S. P., Li, S., Rabhar, Z., Kim, et al  
AMER SOC HEMATOLOGY.2016
- **Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study**  
Kim, Y. H., Whittaker, S., Horwitz, S. M., Duvic, M., Dummer, R., Scarisbrick, J. J., Quaglino, P., Zinzani, P., Wolter, P., Wang, Y., Palanca-Wessels, M., Zagadailov, E., Trepicchio, et al  
AMER SOC HEMATOLOGY.2016
  - **First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results**  
Bagot, M., Porcu, P., Ram-Wolff, C., Khodadoust, M., Battistella, M., Marie-Cardine, A., Mathieu, S., Vermeer, M. H., Whittaker, S., Duvic, M., Bensussan, A., Paturel, C., Bonnafous, et al  
AMER SOC HEMATOLOGY.2016
  - **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*  
Kim, Y. H., Tavallae, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al  
2015; 33 (32): 3750-3758
  - **Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.** *Journal of clinical oncology*  
Scarisbrick, J. J., Prince, H. M., Vermeer, M. H., Quaglino, P., Horwitz, S., Porcu, P., Stadler, R., Wood, G. S., Beylot-Barry, M., Pham-Ledard, A., Foss, F., Girardi, M., Bagot, et al  
2015; 33 (32): 3766-3773
  - **Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.** *Nature genetics*  
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., Zehnder, A., Ohgami, R., Kulkarni, S., Armstrong, R., Weng, W., Gratzinger, D., Tavallae, et al  
2015; 47 (9): 1056-1060
  - **Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2** *NATURE GENETICS*  
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., Zehnder, A., Ohgami, R., Kulkarni, S., Armstrong, R., Weng, W., Gratzinger, D., Tavallae, et al  
2015; 47 (9): 1056-?
  - **Individuality and variation of personal regulomes in primary human T cells.** *Cell systems*  
Qu, K., Zaba, L. C., Giresi, P. G., Li, R., Longmire, M., Kim, Y. H., Greenleaf, W. J., Chang, H. Y.  
2015; 1 (1): 51-61
  - **Individuality and Variation of Personal Regulomes in Primary Human T Cells** *CELL SYSTEMS*  
Qu, K., Zaba, L. C., Giresi, P. G., Li, R., Longmire, M., Kim, Y. H., Greenleaf, W. J., Chang, H. Y.  
2015; 1 (1): 51-61
  - **Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials.** *Journal of the American Academy of Dermatology*  
Hoppe, R. T., Harrison, C., Tavallae, M., Bashey, S., Sundram, U., Li, S., Million, L., Dabaja, B., Gangar, P., Duvic, M., Kim, Y. H.  
2015; 72 (2): 286-292
  - **Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS)**  
Weng, W., Armstrong, R., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Benjamin, J. E., Negrin, R. S., Reddy, S., Million, L., Hoppe, et al  
AMER SOC HEMATOLOGY.2014
  - **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression**  
Kim, Y. H., Tavallae, M., Rozati, S., Sundram, U., Salva, K., Wood, G. S., Li, S., Krathen, M., Nagpal, S., Reddy, S., Armstrong, R., Hoppe, R. T., Pulitzer, et al  
AMER SOC HEMATOLOGY.2014

- **Low Dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides (mf): Results of Three Phase 2 Clinical Trials** *56th Annual Meeting of the American-Society-for-Radiation-Oncology*  
Hoppe, R. T., Harrison, C., Tavallae, M., Bashey, S., Li, S., Million, L., Dabaja, B., Duvic, M., Kim, Y. H.  
ELSEVIER SCIENCE INC.2014: S151–S151
- **Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma** *SCIENCE TRANSLATIONAL MEDICINE*  
Weng, W., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., Kim, Y. H.  
2013; 5 (214)
- **Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.** *Science translational medicine*  
Weng, W., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., Kim, Y. H.  
2013; 5 (214): 214ra171-?
- **Topical Chemotherapy in Cutaneous T-cell Lymphoma Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides** *JAMA DERMATOLOGY*  
Lessin, S. R., Duvic, M., Guitart, J., Pandya, A. G., Strober, B. E., Olsen, E. A., Hull, C. M., Knobler, E. H., Rook, A. H., Kim, E. J., Naylor, M. F., Adelson, D. M., Kimball, et al  
2013; 149 (1): 25-32
- **Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts** *BLOOD*  
Lee, C. S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D. E., Armstrong, R., Weng, W., Aros, C. J., Mah, A., Chen, R. O., Lin, M., Sundram, U., Chang, et al  
2012; 120 (16): 3288-3297
- **Romidepsin Is Effective in Subcutaneous Panniculitis-Like T-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*  
Bashey, S., Krathen, M., Abdulla, F., Sundram, U., Kim, Y. H.  
2012; 30 (24): E221-E225
- **Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma** *BLOOD*  
Horwitz, S. M., Kim, Y. H., Foss, F., Zain, J. M., Myskowski, P. L., Lechowicz, M. J., Fisher, D. C., Shustov, A. R., Bartlett, N. L., Delioukina, M. L., Koutsoukos, T., Saunders, M. E., O'Connor, et al  
2012; 119 (18): 4115-4122
- **In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study** *BLOOD*  
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., Tibshirani, R. J., Advani, R. H., Lingala, et al  
2012; 119 (2): 355-363
- **REVISITING LOW-DOSE TOTAL SKIN ELECTRON BEAM THERAPY IN MYCOSIS FUNGOIDES** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*  
Harrison, C., Young, J., Navi, D., Riaz, N., Lingala, B., Kim, Y., Hoppe, R.  
2011; 81 (4): E651-E657
- **In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J., Czerwinski, D., Xing, L., Morales, A., Ai, W., Abdulla, F., Navi, D., Tibshirani, R. J., Advani, R., Natkunam, et al  
AMER SOC HEMATOLOGY.2010: 130–30
- **Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Horwitz, S. M., Kim, Y. H., Foss, F. M., Zain, J. M., Myskowski, P., Lechowicz, M. J., Fisher, D. C., Shustov, A., Bartlett, N. L., Delioukina, M. L., Koutsoukos, T., Fruchtman, S. M., O'Connor, et al  
AMER SOC HEMATOLOGY.2010: 1154–55
- **Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*

- Whittaker, S. J., Demierre, M., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Kim, et al  
2010; 28 (29): 4485-4491
- **In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study** *JOURNAL OF CLINICAL ONCOLOGY*  
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., Wapnir, I., Tibshirani, R. J., Levy, et al  
2010; 28 (28): 4324-4332
  - **Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome** *49th Annual Meeting of the American-Society-of-Hematology*  
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., Hoppe, R. T., Kim, Y. H.  
AMER MEDICAL ASSOC.2009: 667-74
  - **Low dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose finding trial** *10th International Conference on Malignant Lymphoma*  
Horwitz, S., Duvic, M., Kim, Y., Chance, L., Myskowski, P., Talpur, R., MORALES, A., Saunders, M., O'Connor, O.  
OXFORD UNIV PRESS.2008: 162-162
  - **TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)** *BLOOD*  
Kim, Y. H., Willemze, R., Pimpinelli, N., Whittaker, S., Olsens, E. A., Ranki, A., Dummer, R., Hoppe, R. T.  
2007; 110 (2): 479-484
  - **Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma** *BLOOD*  
Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Osterborg, A., Whittaker, S., Illidge, T. M., Schwarz, T., Kaufmann, R., Cooper, K., Knudsen, K. M., Lisby, et al  
2007; 109 (11): 4655-4662
  - **Novel in situ vaccination with intratumoral injection of CpG 7909, a TLR 9 agonist, combined with radiation in mycosis fungoides and primary cutaneous B-cell lymphoma** *68th Annual Meeting of the Society-for-Investigative-Dermatology*  
Morales, A. V., Hoppe, R., Shah, S., Levy, R., Kim, Y.  
NATURE PUBLISHING GROUP.2007: S43-S43
  - **TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909.** *46th Annual Meeting of the American-Society-of-Hematology*  
Kim, Y., Girardi, M., Duvic, M., Kuzel, T., Rook, A., Link, B., Pinter-Brown, L., Comerchi, C., McAuley, S., Schmalbach, T.  
AMER SOC HEMATOLOGY.2004: 212A-213A
  - **HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma** *65th Annual Meeting of the Society-for-Investigative-Dermatology*  
Kim, Y. H., Obitz, E., Iversen, L., Oesterborg, A., Whittaker, S., Illidge, T. M., Schwarz, T., Kaufmann, R., Gniadecki, R., Duvic, M., Cooper, K., Jensen, P., Baadsgaard, et al  
NATURE PUBLISHING GROUP.2004: A57-A57
  - **Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides**  
de Coninck, E., Kim, Y., Varghese, A., Hoppe, R.  
NATURE PUBLISHING GROUP.2001: 534-34
  - **Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.** *The Journal of dermatological treatment*  
Foss, F., Kim, Y. H., Scarisbrick, J., Akilov, O., Ristuccia, R., Dwyer, K., Wu, W., Bagot, M.  
2025; 36 (1): 2438794
  - **Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial.**  
Porcu, P., Bagot, M., Kim, Y. H., Ram-Wolff, C., Geskin, L. J., Ortiz-Romero, P. L., Kim, E. J., Mehta-Shah, N., Dereure, O., Ingen-Housz-Oro, S., Beylot-Barry, M., Dalle, S., Jacobsen, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: 2522
  - **Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Long-term follow-up and translational data from the TELLOMAK phase 2 trial.**

Porcu, P., Kim, Y. H., Bagot, M., Ram-Wolff, C., Huen, A., Dalle, S., Mehta-Shah, N., Poligone, B., Modeste, A., Zinzani, P., Woei-A-Jin, F., Combalia, A., Eigentler, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: 2523

- **Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides.** *Journal of the European Academy of Dermatology and Venereology : JEADV*  
Kersten, J. M., Ottevanger, R., Quint, K. D., Vermeer, M. H., Goeman, J. J., Kim, Y., Evison, F., Scarisbrick, J. J., Willemze, R.  
2025
- **ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides - a modified Delphi consensus. Part 1: Diagnosis and staging.** *The British journal of dermatology*  
Hodak, E., Amitay-Laish, I., Bagot, M., Battistella, M., Ben Amitai, D., Cozzio, A., Duvic, M., Ferenczi, K., Foss, F., Geskin, L., Guenova, E., Kim, Y. H., Koh, et al  
2025
- **ISCL/EORTC-CLTG/USCLC Recommendations for the Diagnosis, Staging and Treatment of Early-stage Paediatric Mycosis Fungoides - a Modified Delphi Consensus. Part 2: Treatment.** *The British journal of dermatology*  
Hodak, E., Amitay-Laish, I., Bagot, M., Battistella, M., Amitai, D. B., Cozzio, A., Duvic, M., Ferenczi, K., Foss, F., Geskin, L., Guenova, E., Kim, Y. H., Koh, et al  
2025
- **Addiction of primary cutaneous  $\gamma\delta$  T cell lymphomas to JAK/STAT signaling.** *The Journal of clinical investigation*  
Zhang, Y., Yescas, J. A., Tefft, K., Ng, S., Qiu, K., Wang, E. B., Akhtar, S., Walker, A., Welborn, M., Zaiac, M., Guitart, J., Qureshi, A. M., Kim, et al  
2025; 135 (8)
- **ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.** *Journal of the American Academy of Dermatology*  
Goyal, A., O'Leary, D., Dabaja, B., Weng, W. K., Zain, J., Cutler, C., Guitart, J., Kim, Y. H., Geskin, L. J., Hoppe, R. T., Wilson, L. D., Beaven, A. W., Horwitz, et al  
2025
- **Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.** *Leukemia & lymphoma*  
Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., Kim, Y. H., Wilcox, R. A., Patel, M. R., Coffey, G., Innes, A., Betz, A., Holland, et al  
2025: 1-11
- **Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Foss, F. M., Kim, Y. H., Prince, H. M., Akilov, O. E., Querfeld, C., Seminario-Vidal, L., Fisher, D. C., Kuzel, T. M., Yannakou, C. K., Geskin, L. J., Feldman, T., Sokol, L., Allen, et al  
2024: JCO2401549
- **Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.** *The Lancet. Oncology*  
Iyer, S. P., Sica, R. A., Ho, P. J., Prica, A., Zain, J., Foss, F. M., Hu, B., Beitinjane, A., Weng, W. K., Kim, Y. H., Khodadoust, M. S., Huen, A. O., Williams, et al  
2024
- **Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.** *Nature medicine*  
Horwitz, S. M., Nirmal, A. J., Rahman, J., Xu, R., Drill, E., Galasso, N., Ganesan, N., Davey, T., Hancock, H., Perez, L., Maccaro, C., Bahgat, A., Marzouk, et al  
2024
- **Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule**  
Querfeld, C., Scarisbrick, J. J., Akilov, O., Arora, P., Liu, Y., Bagot, M., Cordoba, R., Cowan, R., Garcia-Sancho, A., Geskin, L. J., Huen, A. O., Jadwani, J., Morris, et al  
ELSEVIER.2024: 3056-3058
- **Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization**

Zain, J., Iyer, S. P., Marchi, E., Gandhi, M., Kim, Y. H., Khodadoust, M. S., Brammer, J. E., Poh, C., Porcu, P., Dilley, K., Will, M., Kantor, A., Leonowens, et al  
ELSEVIER.2024: 980-982

- **Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial**  
Bagot, M., Kim, Y. H., Ram-Wolff, C., Dalle, S., Mehta-Shah, N., Huen, A., Poligone, B., Zinzani, P., Geskin, L. J., Duval-Modeste, A., Ortiz-Romero, P. L., Sokol, L., Woei-A-Jin, et al  
ELSEVIER.2024: 467-468
- **Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)**  
Feldman, T., Lee, H., Popradi, G., Collins, G. P., Morillo, D., Yan, M., Chen, T., Kim, Y. H.  
ELSEVIER.2024: 6356-6357
- **Lacutamab in Patients with Relapsed and/or Refractory Sezary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial**  
Battistella, M., Gru, A. A., Moins-Teisserenc, H., Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Sokol, L., Beylot-Barry, et al  
ELSEVIER.2024
- **ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.** *Transplantation and cellular therapy*  
Goyal, A., O'Leary, D., Dabaja, B., Weng, W. K., Zain, J., Cutler, C., Guitart, J., Kim, Y. H., Geskin, L. J., Hoppe, R. T., Wilson, L. D., Beaven, A. W., Horwitz, et al  
2024
- **Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.** *Nature medicine*  
Horwitz, S. M., Nirmal, A. J., Rahman, J., Xu, R., Drill, E., Galasso, N., Ganesan, N., Davey, T., Hancock, H., Perez, L., Maccaro, C., Bahgat, A., Marzouk, et al  
2024
- **Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.**  
Porcu, P., Bagot, M., Ram-Wolff, C., Kim, Y. H., Huen, A., Dalle, S., Poligone, B., Mehta-Shah, N., Modeste, A., Zinzani, P., Woei-A-Jin, F., Eigentler, T., Combalia, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma.** *Cell reports. Medicine*  
Glass, D. R., Mayer-Blackwell, K., Ramchurren, N., Parks, K. R., Duran, G. E., Wright, A. K., Bastidas Torres, A. N., Islas, L., Kim, Y. H., Fling, S. P., Khodadoust, M. S., Newell, E. W.  
2024: 101527
- **Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements.** *Journal of hematopathology*  
Wadsworth, P. A., Lawrence, L., Suarez, C. J., Saleem, A., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., Fernandez-Pol, S.  
2023; 16 (4): 227-234
- **Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements** *JOURNAL OF HEMATOPATHOLOGY*  
Wadsworth, P. A., Lawrence, L., Suarez, C. J., Saleem, A., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., Fernandez-Pol, S.  
2023
- **Lacutamab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial**  
Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Beylot-Barry, M., Dalle, S., Jacobsen, E., Lansigan, F., Ram-Wolff, et al  
AMER SOC HEMATOLOGY.2023
- **Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma**  
Schreidah, C. M., DeStephano, D. M., Pan, S. S., Wang, S., Shen, H., Ta, C. N., Reynolds, G., Fahmy, L. M., Gordon, E. R., Adeuyan, O., Kwinta, B. D., Stonesifer, C. J., Chan, et al  
AMER SOC HEMATOLOGY.2023
- **Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability**

- Munayirji, B., Khan, N., Myskowski, P., Geller, S., Noor, S., Kheterpal, M., Davey, T., Hancock, H., Perez, L., Miller, T., Brutus, J., Ganesan, N., Chang, et al  
AMER SOC HEMATOLOGY.2023
- **Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sezary Syndrome**  
Shinohara, M. M., Kim, Y. H., Molloy, K., Quaglino, P., Scarisbrick, J., Thornton, S. R., Sandilands, K., Liu, J. E., Nixon, A., Williams, A., Ortiz-Romero, P. L.  
AMER SOC HEMATOLOGY.2023
  - **Primary Cutaneous CD30+Large T Cell Lymphoproliferative Disorder Associated With Prolonged Exposure to Fingolimod**  
Cooper, J., Soneji, D., Rieger, K., Narala, S., Kim, Y.  
SAGE PUBLICATIONS LTD.2023: 969
  - **Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning**  
Schreidah, C. M., Reynolds, G., Shen, H., Fahmy, L. M., Choi, J., Duvic, M., Gallardo, F., Girardi, M., Guitart, J., Kim, Y. H., Khodadoust, M., Najidh, S., Ni, et al  
ELSEVIER SCI LTD.2023: S15
  - **Prognostic factors in mycosis fungoides and Sezary syndrome: results from the PROCLIFI study**  
Scarisbrick, J., Evison, F., Kim, Y. H.  
ELSEVIER SCI LTD.2023: S15
  - **Blood tumour burden does not correlate with skin tumour burden in early-stage mycosis fungoides (MF): PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIFI) registry analysis**  
Charalambides, M., Evison, F., Kim, Y. H., Scarisbrick, J., PROCLIFI Investigator Grp  
ELSEVIER SCI LTD.2023: S30
  - **Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study**  
Bagot, M., Kim, Y. H., Ortiz-Romero, P. L., Zinzani, P., Beylot-Barry, M., Dalle, S., Jacobsen, E., Combalia, A., Huen, A., Mehta-Shah, N., Khodadoust, M., Mehta, A., Dereure, et al  
ELSEVIER SCI LTD.2023: S19-S20
  - **Health-related quality of life (HRQL) in cutaneous T-cell lymphoma: burden of disease and patient characteristics from a post-hoc analysis of a phase 3 trial in mycosis fungoides and Sezary syndrome**  
Romero, P., Nixon, A., Kim, Y. H., Molloy, K., Quaglino, P., Scarisbrick, J., Thornton, S., Sandilands, K., Liu, J., Nixon, A., Williams, A., Shinohara, M.  
ELSEVIER SCI LTD.2023: S38
  - **ISCL/USCLC/EORTC guidelines for the diagnosis, staging, and treatment of pediatric mycosis fungoides**  
Hodak, E., Amitay-Laish, I., Bagot, M., Battistella, M., Cozzio, A., Duvic, M., Geskin, L., Guenova, E., Kim, Y. H., Nicolay, J., Ortiz-Romero, P., Osmanovic, A., Papadavid, et al  
ELSEVIER SCI LTD.2023: S5-S6
  - **Identifying and addressing unmet clinical needs in primary cutaneous B-cell lymphoma: A consensus-based paper from an ad-hoc international panel.** *Hematological oncology*  
Quaglino, P., Pimpinelli, N., Zinzani, P. L., Paulli, M., Pileri, S., Berti, E., Cerroni, L., Guitart, J., Kim, Y. H., Rupoli, S., Santucci, M., Simontacchi, G., Vermeer, et al  
2023
  - **Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma.** *Journal of cutaneous pathology*  
Lawrence, L., Wang, A., Charville, G., Liu, C. L., Garofalo, A., Alizadeh, A., Jangam, D., Pinsky, B. A., Sahoo, M., Gratzinger, D., Khodadoust, M., Kim, Y., Novoa, et al  
2023
  - **Minimal/measurable residual disease (MRD) monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor.** *The Journal of molecular diagnostics : JMD*  
Tung, J. K., Jangam, D., Ho, C. C., Fung, E., Khodadoust, M. S., Kim, Y. H., Zehnder, J. L., Stehr, H., Zhang, B. M.  
2023
  - **Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases.** *JCO precision oncology*

- Narala, S., Che, Y., Saleem, A., Lock, C. B., Kim, Y. H., Rieger, K. E.  
2023; 7: e2200501
- **Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey.** *Journal of the European Academy of Dermatology and Venereology : JEADV*  
Quaglino, P., Scarisbrick, J., Rocuzzo, G., Abeldano, A., Battistella, M., McCormack, C., Cowan, R., Cozzio, A., Cury-Martins, J., Enz, P., Geskin, L., Guenova, E., Kim, et al  
2023
  - **Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial**  
Bagot, M., Kim, Y. H., Ortiz-Romero, P. L., Zinzani, P., Mehta-Shah, N., Dereure, O., Beylot-Barry, M., Dalle, S., Jacobsen, E. D., Huen, A., Combalia, A., Battistella, M., Gru, et al  
AMER SOC HEMATOLOGY.2022: 3760-3761
  - **ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas**  
Song, Y., Ding, N., Yoon, D., Reneau, J. C., Wilcox, R. A., Kim, W., Kim, Y. H., Khodadoust, M. S., Feldman, T. A., Yannakou, C. K., Giri, P., Brammer, J. E., Hsu, et al  
AMER SOC HEMATOLOGY.2022: 8857-8859
  - **Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302**  
Foss, F. M., Kim, Y. H., Prince, H., Kuzel, T. M., Yannakou, C. K., Ooi, C., Xing, D., Sauter, N., Singh, P., Czuczman, M., Duvic, M.  
AMER SOC HEMATOLOGY.2022: 1491-1492
  - **Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas**  
Mou, E., Fernandez-Pol, S., Li, S., Kim, Y. H., Khodadoust, M. S.  
AMER SOC HEMATOLOGY.2022: 6552-6553
  - **Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis.** *JAMA oncology*  
Cai, Z. R., Chen, M. L., Weinstock, M. A., Kim, Y. H., Novoa, R. A., Linos, E.  
2022
  - **Clinical and Pathological Characteristics and Outcomes Among Patients With Subcutaneous Panniculitis-like T-Cell Lymphoma and Related Adipotropic Lymphoproliferative Disorders.** *JAMA dermatology*  
Guitart, J., Mangold, A. R., Martinez-Escala, M. E., Walker, C. J., Comfere, N. I., Pulitzer, M., Rieger, K. E., Torres-Cabala, C. A., Pincus, L. B., Kumar, E. S., Wang, E. B., Park, K. E., Espinosa, et al  
2022
  - **Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.** *The oncologist*  
Jagadeesh, D., Horwitz, S., Bartlett, N. L., Kim, Y., Jacobsen, E., Duvic, M., Little, M., Trepicchio, W., Fenton, K., Onsum, M., Lisano, J., Advani, R.  
2022
  - **Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.** *JAMA dermatology*  
Kim, E. J., Mangold, A. R., DeSimone, J. A., Wong, H. K., Seminario-Vidal, L., Guitart, J., Appel, J., Geskin, L., Lain, E., Korman, N. J., Zeitouni, N., Nikbakht, N., Dawes, et al  
2022
  - **Correlation of sTNFR2 elevation and disease progression in cutaneous T cell lymphomas**  
Lee, A., Kim, Y., Khodadoust, M., Faustman, D. L.  
AMER ASSOC CANCER RESEARCH.2022
  - **Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.** *American journal of clinical dermatology*  
Querfeld, C., Scarisbrick, J. J., Assaf, C., Kim, Y. H., Guitart, J., Quaglino, P., Hodak, E.  
2022
  - **T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Brammer, J., Clemens, M. W., Dogan, A., Foss, F., Ghione, P., Goodman, A. M., Guitart, J., Halwani, et al

2022; 20 (3): 285-308

- **What factors guide treatment selection in mycosis fungoides and Sezary syndrome?** *Hematology. American Society of Hematology. Education Program*  
Kim, Y. H.  
2021; 2021 (1): 303-312
- **Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral TCell Lymphoma**  
Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., Kim, Y. H., Wilcox, R. A., Patel, M. R., Coffey, G. P., Osman, M., Holland, J. S., Guzman, et al  
AMER SOC HEMATOLOGY.2021
- **Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies**  
Horwitz, S. M., Foran, J. M., Maris, M., Lue, J., Sawas, A., Okada, C., Feldman, T. A., Sokol, L., Mei, M., Flinn, I. W., Villa, D., Percival, M. M., Jagadeesh, et al  
AMER SOC HEMATOLOGY.2021
- **Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion.** *JCO precision oncology*  
Fernandez-Pol, S., Neishaboori, N., Chapman, C. M., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., Suarez, C. J.  
2021; 5: 646-652
- **Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.** *European journal of cancer (Oxford, England : 1990)*  
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., Herr, F., Bagot, M.  
2021; 156 Suppl 1: S48-S49
- **Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial**  
Musiek, A. C. M., Whittaker, S., Horowitz, S. M., Bagot, M., Huen, A., Fisher, D. C., Haun, P., Vermeer, M. H., Ito, T., Dwyer, K., Herr, F., Kim, Y. H.  
ELSEVIER SCI LTD.2021: S46
- **Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study**  
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., Herr, F., Bagot, M.  
ELSEVIER SCI LTD.2021: S48-S49
- **Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial**  
Bagot, M., Kim, Y., Zinzani, P., Dalle, S., Beylot-Barry, M., Ortiz-Romero, P. L., Cambalia, A., Dereure, O., Mortier, L., Jacobsen, E., Battistella, M., Gru, A., Moins-Teisserenc, et al  
ELSEVIER SCI LTD.2021: S20-S21
- **Time-to-next-treatment and time-to-next-systemic treatment in patients included in the PROCLIFI registry**  
Quaglino, P., Ortiz-Romero, P., Bagot, M., Cozzio, A., Evison, F., Geskin, L., Guenova, E., Hodak, E., Horwitz, S., Papadavid, E., Porcu, P., Prince, M., Stadler, et al  
ELSEVIER SCI LTD.2021: S28
- **Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma**  
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Kim, Y., Khodadoust, M.  
ELSEVIER SCI LTD.2021: S8
- **Prognostic factors in mycosis fungoides and Sezary syndrome: results from the PROCLIFI study**  
Scarisbrick, J. J., Kim, Y. H.  
ELSEVIER SCI LTD.2021: S28-S29
- **Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial.** *European journal of cancer (Oxford, England : 1990)*  
Musiek, A. C., Whittaker, S., Horowitz, S. M., Bagot, M., Huen, A., Fisher, D. C., Haun, P., Vermeer, M. H., Ito, T., Dwyer, K., Herr, F., Kim, Y. H.  
2021; 156 Suppl 1: S46
- **Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.** *Blood advances*

- Horwitz, S. M., Scarisbrick, J. J., Dummer, R., Whittaker, S., Duvic, M., Kim, Y. H., Quaglino, P., Zinzani, P. L., Bechter, O., Eradat, H., Pinter-Brown, L., Akilov, O. E., Geskin, et al  
2021
- **Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study.** *Journal of the American Academy of Dermatology*  
Querfeld, C., Kim, Y. H., Guitart, J., Scarisbrick, J., Quaglino, P.  
2021
  - **Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.** *Leukemia & lymphoma*  
Horwitz, S., Zinzani, P. L., Bagot, M., Kim, Y. H., Moskowitz, A. J., Porcu, P., Dwyer, K., Sun, W., Herr, F. M., Scarisbrick, J.  
2021: 1-10
  - **Technical report: 3D-printed patient-specific scalp shield for hair preservation in total skin electron beam therapy.** *Technical innovations & patient support in radiation oncology*  
Rahimy, E., Skinner, L., Kim, Y. H., Hoppe, R. T.  
2021; 18: 12-15
  - **Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation.** *Cancer investigation*  
Wu, Y. F., Skinner, L., Lewis, J., Khodadoust, M. S., Kim, Y. H., Kwong, B. Y., Weng, W., Hoppe, R. T., Sodji, Q., Hui, C., Kastelowitz, N., Fernandez-Pol, S., Hiniker, et al  
2021: 1-11
  - **Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion** *JCO PRECISION ONCOLOGY*  
Fernandez-Pol, S., Neishaboori, N., Chapman, C. M., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., Suarez, C. J.  
2021; 5: 646-652
  - **Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.** *Dermatology and therapy*  
Musiek, A. C., Rieger, K. E., Bagot, M., Choi, J. N., Fisher, D. C., Guitart, J., Haun, P. L., Horwitz, S. M., Huen, A. O., Kwong, B. Y., Lacouture, M. E., Noor, S. J., Rook, et al  
2021
  - **Next generation sequencing confirms T-cell clonality in a subset of pediatric pityriasis lichenoides.** *Journal of cutaneous pathology*  
Raghavan, S. S., Wang, J. Y., Gru, A. A., Marqueling, A. L., Teng, J. M., Brown, R. A., Novoa, R. A., Kim, Y., Zehnder, J., Zhang, B. M., Rieger, K. E.  
2021
  - **Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study.** *Clinical lymphoma, myeloma & leukemia*  
Geskin, L. J., Kim, E. J., Angello, J. T., Kim, Y. H.  
2020
  - **Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations.** *The American journal of surgical pathology*  
Fernandez-Pol, S., Petersen, B., Murphy, J., Oak, J. S., Wang, E. B., Rieger, K. E., Kim, Y. H., Khodadoust, M. S., Suarez, C. J.  
2020
  - **Safety of Mogamulizumab in Mycosis Fungoides and Sezary Syndrome: Final Results from the Phase 3 MAVORIC Study**  
Sokol, L., Duvic, M., Musiek, A., Kim, E., Eradat, H., Elmets, C., Shinohara, M., Fisher, D., Poligone, B., Pro, B., Reddy, N., Halwani, A., Herr, et al  
CIG MEDIA GROUP, LP.2020: S253
  - **Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma.** *Cancers*  
Campbell, B. A., Scarisbrick, J. J., Kim, Y. H., Wilcox, R. A., McCormack, C., Prince, H. M.  
2020; 12 (8)
  - **Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.** *European journal of cancer (Oxford, England : 1990)*  
Dummer, R., Prince, H. M., Whittaker, S., Horwitz, S. M., Kim, Y. H., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Eradat, H., Pinter-Brown, L., Sanches, J. A., Ortiz-Romero, et al  
2020; 133: 120-30

- **Primary Cutaneous Lymphomas Version 2.2020 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Mehta-Shah, N., Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Clemens, M. W., Dogan, A., Fisher, K., Goodman, A. M., Goyal, G., Guitart, J., Halwani, et al  
2020; 18 (5): 523–36
- **NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Clemens, M. W., Dogan, A., Goodman, A. M., Goyal, G., Guitart, J., Halwani, A., Haverkos, B. M., Hoppe, et al  
2020; 18 (11): 1460–67
- **Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging**  
Schuerch, C. M., Phillips, D. J., Bhate, S. S., Barlow, G. L., Fling, S. P., Ramchurren, N., Pierce, R., Cheever, M. A., Khodadoust, M. S., Kim, Y. H., Nolan, G. P.  
AMER SOC HEMATOLOGY.2019
- **Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells**  
Ng, P. P., Mobasher, M., Yeung, K. S., Hotson, A. N., Hill, C. M., Madriaga, A., Dao-Pick, T. P., Verner, E., Radeski, D., Khodadoust, M. S., Kim, Y. H., Miller, R. A., Buggy, et al  
AMER SOC HEMATOLOGY.2019
- **Safety of Mogamulizumab in Mycosis Fungoides and Sezary Syndrome: Final Results from the Phase 3 Mavoric Study**  
Kim, Y. H., Bagot, M., Zinzani, P., Duvic, M., Morris, S., Kim, E., Musiek, A., Ortiz-Romero, P. L., Elmets, C., Eradat, H. A., Magnolo, N., Scarisbrick, J., Dalle, et al  
AMER SOC HEMATOLOGY.2019
- **A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/ Refractory T-Cell Lymphoma**  
Mobasher, M., Miller, R. A., Janc, J. W., Kwei, L., Buggy, J. J., Luciano, G., Mohammady, A., Kim, W., Kim, Y. H., Khodadoust, M. S., Horwitz, S. M., Radeski, D.  
AMER SOC HEMATOLOGY.2019
- **Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells**  
Ng, P. P., Mobasher, M., Yeung, K. S., Hotson, A. N., Hill, C. M., Madriaga, A., Dao-Pick, T. P., Verner, E., Radeski, D., Khodadoust, M. S., Kim, Y. H., Miller, R. A., Buggy, et al  
AMER SOC HEMATOLOGY.2019
- **Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor**  
Khodadoust, M., Kim, Y., Yang, M., Torrey, H., Tran, L., Faustman, D.  
BMC.2019
- **Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Kheterpal, M. K., Dai, J., Geller, S., Pulitzer, M., Ni, A., Myskowski, P. L., Moskowitz, A., Kim, J., Hong, E. K., Fong, S., Hoppe, R. T., Kim, Y. H., Horwitz, et al  
2019; 81 (4): 970–76
- **Time to Next Treatment in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) Receiving Mogamulizumab or Vorinostat: A MAVORIC Post-Hoc Analysis**  
Sokol, L., Kim, Y. H., Ortiz-Romero, P. L., Pro, B., Scarisbrick, J., Musiek, A., Vermeer, M., Dummer, R., Halwani, A., Fierro, M., Moriya, J., Leoni, M., Bagot, et al  
CIG MEDIA GROUP, LP.2019: S361
- **Angiodestructive lymphomatoid papulosis lasting more than 45years.** *JAAD case reports*  
Lee, G. H., Bae, G. H., Rieger, K. E., Kim, Y. H., Chiou, A. S.  
2019; 5 (9): 767–69

- **Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs** *PRACTICAL RADIATION ONCOLOGY*  
Obeid, J., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., Kim, Y. H., Weng, W., Hoppe, R. T., Hiniker, S. M.  
2019; 9 (4): 220–25
- **Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders.** *The Journal of dermatological treatment*  
Panjwani, N., Yoo, C. H., Wang, E., Khodadoust, M. S., Kim, Y. H., Hoppe, R. T., Hiniker, S. M.  
2019: 1–5
- **Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.**  
Jagadeesh, D., Horwitz, S. M., Bartlett, N. L., Advani, R. H., Jacobsen, E. D., Duvic, M., Gautam, A., Rao, S., Onsum, M., Fanale, M., Kim, Y. H.  
AMER SOC CLINICAL ONCOLOGY.2019
- **Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAJORIC post-hoc analysis.**  
Pro, B., Kim, Y. H., Ortiz-Romero, P. L., Sokol, L., Scarisbrick, J., Musiek, A., Vermeer, M., Dummer, R., Halwani, A., Fierro, M., Moriya, J., Leoni, M., Bagot, et al  
AMER SOC CLINICAL ONCOLOGY.2019
- **Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sezary syndrome.** *British journal of haematology*  
Jothishankar, B., Almazan, T., Kim, Y., Liauw, S., Smith, S., Kline, J., Abdulla, F.  
2019
- **Measurement of Quality of Life in Patients with Mycosis Fungoides/Sezary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument** *JOURNAL OF MEDICAL INTERNET RESEARCH*  
McCaffrey, S., Black, R. A., Nagao, M., Sepassi, M., Sharma, G., Thornton, S., Kim, Y. H., Braverman, J.  
2019; 21 (1): e11302
- **Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study**  
Scarisbrick, J., Horwitz, S. M., Prince, H., Whittaker, S., Duvic, M., Kim, Y. H., Quaglino, P., Zinzani, P., Bechter, O., Eradat, H., Pinter-Brown, L., Akilov, O., Geskin, et al  
ELSEVIER SCI LTD.2019: S31
- **Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation** *JOURNAL OF CUTANEOUS PATHOLOGY*  
Raghavan, S. S., Hong, E. K., Kim, Y. H., Kim, J.  
2019; 46 (1): 33–43
- **Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin.** *Journal of the American Academy of Dermatology*  
Khetarpal, M. K., Dai, J. n., Geller, S. n., Pulitzer, M. n., Ni, A. n., Myskowski, P. L., Moskowitz, A. n., Kim, J. n., Hong, E. K., Fong, S. n., Hoppe, R. T., Kim, Y. H., Horwitz, et al  
2019
- **Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma** *NEOPLASIA*  
Zhao, L., Okhovat, J., Hong, E. K., Kim, Y. H., Wood, G. S.  
2019; 21 (1): 82–92
- **Defining B2 involvement in Sezary syndrome results from the PROCLIP study**  
Hunjan, M., Bagot, M., Guenova, E., Horwitz, S., Quaglino, P., Child, F., Berti, E., Ortiz, P., Servitje, O., Marschalko, M., Papadavid, E., Beylot-Barry, M., Cowan, et al  
ELSEVIER SCI LTD.2019: S6
- **Folliculotropic mycosis fungoides presents with two distinct clinicopathological presentations: an international virtual study**  
Hodak, E., Zic, J., Bagot, M., Gru, A. A., Battistella, M., Mitteldorf, C., Cozzio, A., Guenova-Hotzenecker, E., Guitart, J., Geskin, L., Knobler, R., Ortiz, P., Papadavid, et al  
ELSEVIER SCI LTD.2019: S27–S28

- **Prognostic factors in mycosis fungoides: the PROCLIFI study**  
Scarlsbrick, J., Quaglino, P., Prince, M., Papadavid, E., Hodak, E., Child, F., Whittaker, S., Bagot, M., Querfeld, C., Akilov, O., Servitje, O., Berti, E., Ortiz-Romero, et al  
ELSEVIER SCI LTD.2019: S26
- **Treatment of early-phase mycosis fungoides: results from the Prospective Cutaneous Lymphoma International (PROCLIFI) study**  
Quaglino, P., Scarlsbrick, J., Prince, M., Papadavid, E., Hodak, E., Child, F., Whittaker, S., Bagot, M., Querfeld, C., Akilov, O., Servitje, O., Berti, E., Ortiz-Romero, et al  
ELSEVIER SCI LTD.2019: S27
- **An international multi-institutional study for the evaluation of folliculotropic mycosis fungoides: results of the Consensus Histopathologic Review**  
Gru, A. A., Mitteldorf, C., Pulitzer, M., Hodak, E., Scarlsbrick, J., Zic, J., Kempf, W., Guenova, E., Haun, P., Torres-Cabala, C., Robson, A., Querfeld, C., Junkins-Hopkins, et al  
ELSEVIER SCI LTD.2019: S26–S27
- **Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Final Results from a Phase 2 Multicenter Study**  
Khodadoust, M. S., Rook, A., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., Shanbhag, S., Sokol, L., Fling, S. P., Li, S., Davis, A., Fong, S., Kim, et al  
AMER SOC HEMATOLOGY.2018
- **Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study**  
Kim, Y. H., Prince, H., Whittaker, S., Horwitz, S. M., Duvic, M., Bechter, O., Sanches, J. A., Stadler, R., Scarlsbrick, J., Quaglino, P., Zinzani, P., Wolter, P., Eradat, et al  
AMER SOC HEMATOLOGY.2018
- **The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma**  
Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., Patel, M. R., Phillips, T. J., Smith, S. D., Smith, S. M., Wilcox, R. A., Steele, A., Pandey, et al  
AMER SOC HEMATOLOGY.2018
- **The Combination of Duvelisib, a PI3K-delta,gamma Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts**  
Horwitz, S. M., Moskowitz, A. J., Jacobsen, E. D., Mehta-Shah, N., Khodadoust, M. S., Fisher, D. C., Myskowski, P., Wang, E. B. K., Tawa, M., Davey, T., Blouin, W., Hancock, H., Ganesan, et al  
AMER SOC HEMATOLOGY.2018
- **Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma**  
Querfeld, C., Foss, F. M., Kim, Y. H., Pinter-Brown, L., William, B. M., Porcu, P., Pacheco, T., Haverkos, B. M., DeSimone, J., Guitart, J., Halwani, A. S., Eradat, H. A., Huen, et al  
AMER SOC HEMATOLOGY.2018
- **Long-Term Clinical Benefit to Anti-CCR4 Mogamulizumab: Results from the Phase 3 Mavoric Study in Previously Treated Cutaneous T-Cell Lymphoma (CTCL)**  
Bagot, M., Dalle, S., Sokol, L., Tsianakas, A., Musiek, A., Ortiz-Romero, P., Poligone, B., Duvic, M., Elmets, C., Leoni, M., Dwyer, K., Sun, W., Nikonova, et al  
AMER SOC HEMATOLOGY.2018
- **Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation. *Journal of cutaneous pathology***  
Raghavan, S. S., Hong, E. K., Kim, Y. H., Kim, J.  
2018
- **Pembrolizumab in mycosis fungoides and Sezary syndrome: Updated results of the CITN multicenter Phase 2 study**  
Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A., Shustov, A. R., Shanbhag, S., Sokol, L., Fling, S. P., Li, S., Fong, S., Kim, J., Yang, et al  
ELSEVIER SCI LTD.2018: S37

- **Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma** *PHOTOCHEMISTRY AND PHOTOBIOLOGY*  
Salva, K. A., Kim, Y. H., Rahbar, Z., Wood, G. S.  
2018; 94 (5): 1058–65
- **Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sezary Syndrome** *JAMA DERMATOLOGY*  
Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W., Kim, Y. H.  
2018; 154 (6): 728–30
- **Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.**  
Foss, F. M., Querfeld, C., Kim, Y. H., Pinter-Brown, L. C., William, B. M., Porcu, P., Pacheco, T., Haverkos, B., DeSimone, J., Guitart, J., Halwani, A., Eradat, H., Huen, et al  
AMER SOC CLINICAL ONCOLOGY.2018
- **The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?** *The British journal of dermatology*  
Geller, S., Myskowski, P. L., Kim, Y. H., Moskowitz, A., Horwitz, S.  
2018; 178 (2): 571
- **NCCN Guidelines (R) Insights T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Horwitz, S. M., Ansell, S. M., Ai, W. Z., Barnes, J., Barta, S. K., Choi, M., Clemens, M. W., Dogan, A., Greer, J. P., Halwani, A., Haverkos, B. M., Hoppe, R. T., Jacobsen, et al  
2018; 16 (2): 123–35
- **Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy** *LEUKEMIA & LYMPHOMA*  
Duvic, M., Bates, S. E., Piekarz, R., Eisch, R., Kim, Y. H., Lerner, A., Robak, T., Samtsov, A., Becker, J. C., McCulloch, W., Waksman, J., Whittaker, S.  
2018; 59 (4): 880–87
- **Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.** *JAMA dermatology*  
Dai, J. n., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S. n., Weng, W. K., Kim, Y. H.  
2018
- **Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma** *CLINICAL CANCER RESEARCH*  
Duvic, M., Kim, Y. H., Zinzani, P., Horwitz, S. M.  
2017; 23 (14): 3552–56
- **An adolescent with granulomatous mycosis fungoides infiltrating skeletal muscle successfully treated with oral prednisone.** *JAAD case reports*  
Lewis, D. J., Turkeltaub, A. E., Dai, J., Nagarajan, P., Rieger, K. E., Nunez, C. A., Kim, Y. H., Duvic, M.  
2017; 3 (4): 276–79
- **Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL).**  
Foss, F. M., Querfeld, C., Porcu, P., Kim, Y. H., Pacheco, T., Halwani, A., DeSimone, J., William, B. M., Seto, A. G., Ruckman, J., Landry, M. L., Jackson, A. L., Pestano, et al  
AMER SOC CLINICAL ONCOLOGY.2017
- **Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.** *Journal of neuro-oncology*  
Corbin, Z. A., Nguyen-Lin, A., Li, S., Rahbar, Z., Tavallae, M., Vogel, H., Salva, K. A., Wood, G. S., Kim, Y. H., Nagpal, S.  
2017
- **NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Caimi, P., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, et al  
2017; 15 (3): 293-311

- **Zosteriform Mycosis Fungoides: A New Clinical Presentation With a Dermatomal Distribution.** *The American Journal of dermatopathology*  
Rieger, K. E., Kim, J., Kim, Y. H.  
2017; 39 (2): e17-e18
- **Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation.** *JAAD case reports*  
Amitay-Laish, I. n., Sundram, U. n., Hoppe, R. T., Hodak, E. n., Medeiros, B. C., Kim, Y. H.  
2017; 3 (4): 310-15
- **Neurotropic Gamma-Delta T-Cell Lymphoma With CD30-Positive Lymphoid Infiltrates** *AMERICAN JOURNAL OF DERMATOPATHOLOGY*  
Gammon, B., Gammon, B. R., Kim, Y. H., Kim, J.  
2016; 38 (9): E133-E136
- **Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, et al  
2016; 14 (9): 1067-1079
- **Useful Parameters for Distinguishing Subcutaneous Panniculitis-like T-Cell Lymphoma From Lupus Erythematosus Panniculitis** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*  
LeBlanc, R. E., Tavallaee, M., Kim, Y. H., Kim, J.  
2016; 40 (6): 745-754
- **A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: Interim results.**  
Duvic, M., Kim, Y. H., LeBoeuf, N. R., Porcu, P., Hastings, J., Bassuner, J., Sowerby, L., Posligua-Alban, A., Guitart, J.  
AMER SOC CLINICAL ONCOLOGY.2016
- **First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.**  
Bagot, M., Duvic, M., Vermeer, M., Porcu, P., Whittaker, S., Ram-Wolff, C., Paiva, C., Marie-Cardine, A., Bonnafous, C., Paturel, C., Moriette, F., Zerbib, R., Bensussan, et al  
AMER SOC CLINICAL ONCOLOGY.2016
- **Experimental treatment strategies in primary cutaneous T-cell lymphomas** *CURRENT OPINION IN ONCOLOGY*  
Rozati, S., Kim, Y. H.  
2016; 28 (2): 166-171
- **Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, T. M., Harris, et al  
2016; 14 (2): 196-231
- **Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma**  
Duvic, M., Horwitz, S. M., Kim, Y. H., Zinzani, P., Bhat, G., Sharma, P., Yancik, S.  
AMER SOC HEMATOLOGY.2015
- **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*  
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al  
2015; 33 (32): 3750-3758
- **Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting** *PEDIATRIC BLOOD & CANCER*  
Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., Link, M. P.  
2015; 62 (11): 2025-2028
- **Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma** *LEUKEMIA & LYMPHOMA*

- Kim, E. J., Kim, Y. H., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Waksman, J., Whittaker, S. 2015; 56 (10): 2847-2854
- **Occult Dermal Lymphatic Involvement Is Frequent in Primary Cutaneous Anaplastic Large Cell Lymphoma.** *American Journal of dermatopathology*  
Gratzinger, D., Million, L., Kim, Y. H.  
2015; 37 (10): 767-770
  - **Lymph node involvement by mycosis fungoides and Sezary syndrome mimicking angioimmunoblastic T-cell Lymphoma** *HUMAN PATHOLOGY*  
LeBlanc, R. E., Lefterova, M. I., Suarez, C. J., Tavallaee, M., Kim, Y. H., Schrijver, I., Kim, J., Gratzinger, D.  
2015; 46 (9): 1382-1389
  - **Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.** *Human pathology*  
LeBlanc, R. E., Lefterova, M. I., Suarez, C. J., Tavallaee, M., Kim, Y. H., Schrijver, I., Kim, J., Gratzinger, D.  
2015; 46 (9): 1382-9
  - **KIR3DL2 is a novel target for antibody-therapy of T cell lymphomas**  
Chester, C., Lim, S., Marie-Cardine, A., Rajasekaran, N., Sicard, H., Kim, Y., Kohrt, H.  
AMER ASSOC CANCER RESEARCH.2015
  - **Primary Cutaneous Gamma-Delta T-Cell Lymphoproliferative Disorder in a 3-Year-Old Boy.** *American Journal of dermatopathology*  
Soon, C. W., Link, M., Kim, Y. H., Kim, J.  
2015; 37 (7): 567-569
  - **Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.** *Blood*  
Duvic, M., Pinter-Brown, L. C., Foss, F. M., Sokol, L., Jorgensen, J. L., Challagundla, P., Dwyer, K. M., Zhang, X., Kurman, M. R., Ballerini, R., Liu, L., Kim, Y. H.  
2015; 125 (12): 1883-1889
  - **Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome** *CLINICAL CANCER RESEARCH*  
Ni, X., Jorgensen, J. L., Goswami, M., Challagundla, P., Decker, W. K., Kim, Y. H., Duvic, M. A.  
2015; 21 (2): 274–85
  - **Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study**  
Duvic, M., Kim, Y. H., Rook, A. H., Lerner, A., Robak, T., Samtsov, A., McCulloch, W., Waksman, J., Whittaker, S.  
AMER SOC HEMATOLOGY.2014
  - **A Cutaneous Lymphoma International Consortium 'CLIC' study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging**  
Scarisbrick, J. J., Quaglino, P., Vermeer, M., Whittaker, S., Wood, G. S., Duvic, M., Prince, M., Horwitz, S. M., Hoppe, R. T., Porcu, P., Stadler, R., Evison, F., Kim, et al  
AMER SOC HEMATOLOGY.2014
  - **Use of High-Throughput Sequencing (HTS) of TCR beta to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant**  
Weng, W., Armstrong, R., Arai, S., Hoppe, R. T., Meyer, E. H., Kim, Y. H.  
AMER SOC HEMATOLOGY.2014
  - **Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma**  
Kohrt, H. E., Chu, J., Brody, J., Czerwinski, D. K., Chester, C., Sadaram, M., Advani, R., Kim, Y. H., Hoppe, R. T., Knox, S. J., Wapnir, I., Tibshirani, R. J., Levy, et al  
AMER SOC HEMATOLOGY.2014
  - **A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)**  
Duvic, M., Kuzel, T. M., Dang, N. H., Prince, M., Feldman, T., Foss, F. M., Guo, M., Ottesen, L., Ooi, C., Kim, Y. H.  
AMER SOC HEMATOLOGY.2014

- **Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).** *Annals of oncology*  
Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., Eggmann, N., Goldinger, S. M., Hutchinson, K., Geskin, L., Illidge, T. M., Giuliano, E., Elder, J., Kim, et al  
2014; 25 (9): 1807-1812
- **Non-Hodgkin's Lymphomas, Version 4.2014.** *Journal of the National Comprehensive Cancer Network*  
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, M. J., Harris, et al  
2014; 12 (9): 1282-1303
- **Intralymphatic Cutaneous Anaplastic Large Cell Lymphoma/Lymphomatoid Papulosis: Expanding the Spectrum of CD30-positive Lymphoproliferative Disorders.** *American journal of surgical pathology*  
Samols, M. A., Su, A., Ra, S., Cappel, M. A., Louissant, A., Knudson, R. A., Ketterling, R. P., Said, J., Binder, S., Harris, N. L., Feldman, A. L., Kim, J., Kim, et al  
2014; 38 (9): 1203-1211
- **Outcomes After Diagnosis of Mycosis Fungoides and Sezary Syndrome Before 30 Years of Age A Population-Based Study** *JAMA DERMATOLOGY*  
Ai, W. Z., Keegan, T. H., Press, D. J., Yang, J., Pincus, L. B., Kim, Y. H., Chang, E. T.  
2014; 150 (7): 709-715
- **Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.** *JAMA dermatology*  
Ai, W. Z., Keegan, T. H., Press, D. J., Yang, J., Pincus, L. B., Kim, Y. H., Chang, E. T.  
2014; 150 (7): 709-715
- **Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now?** *BRITISH JOURNAL OF DERMATOLOGY*  
Scarisbrick, J. J., Kim, Y. H., Whittaker, S. J., Wood, G. S., Vermeer, M. H., Prince, H. M., Quaglino, P.  
2014; 170 (6): 1226-1236
- **Non-Hodgkin's Lymphomas, version 2.2014.** *Journal of the National Comprehensive Cancer Network*  
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Fisher, R. I., Glenn, et al  
2014; 12 (6): 916-946
- **Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%.**  
Kim, Y. H., Duvic, M., Guitart, J., Lessin, S.  
AMER SOC CLINICAL ONCOLOGY.2014
- **Phase 3 study of anti-CCR4 monoclonal antibody mogamualizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL)**  
Kim, Y. H., Bagot, M., Eradat, H., Carson, K., Greer, J. P., Kim, E. J., Kuzel, T., Hughey, L. C., Pollgone, B., Lansigan, F., Zinrani, P., Grandinetti, L. M., Porcu, et al  
AMER SOC CLINICAL ONCOLOGY.2014
- **Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement.**  
Foss, F. M., Duvic, M., Lerner, A., Rook, A., Whittaker, S., Kim, E. J., Kim, Y. H.  
AMER SOC CLINICAL ONCOLOGY.2014
- **Multicenter Case Series of Indolent Small/Medium-Sized CD8+ Lymphoid Proliferations With Predilection for the Ear and Face.** *American Journal of dermatopathology*  
Li, J. Y., Guitart, J., Pultizart, M. P., Subtil, A., Sundram, U., Kim, Y., Deonizio, J., Myskowski, P. L., Moskowitz, A., Horwitz, S., Querfeld, C.  
2014; 36 (5): 402-408
- **Utility of high-throughput sequencing of T cell receptor gene rearrangement to improve diagnosis in cutaneous T cell lymphoma** *Annual Meeting of the Society-for-Investigative-Dermatology (SID)*  
Rozati, S., Weng, W., Tavallaee, M., Kim, J., Rieger, K., Armstrong, R., Kirsch, I., Kim, Y. H.  
NATURE PUBLISHING GROUP.2014: S96-S96

- **A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in patients with mycosis fungoides** *Annual Meeting of the Society-for-Investigative-Dermatology (SID)*  
Bashey, S., Tavallae, M., Duvic, M., Dabaja, B., Talpur, R., Wilson, L., Grardi, M., Foss, F., Li, S., Rozati, S., Million, L., Hoppe, R., Kim, et al  
NATURE PUBLISHING GROUP.2014: S104–S104
- **Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome.** *Blood*  
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., Kuzel, T. M.  
2014; 123 (8): 1159-1166
- **Intravascular ALK-negative Anaplastic Large Cell Lymphoma With Localized Cutaneous Involvement and an Indolent Clinical Course Toward Recognition of a Distinct Clinicopathologic Entity** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*  
Metcalf, R. A., Bashey, S., Wysong, A., Kim, J., Kim, Y. H., Gratzinger, D.  
2013; 37 (4): 617-623
- **Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Glenn, M. J., Gockerman, J. P., Gordon, et al  
2013; 11 (3): 257-273
- **Clonal Identity and Differences in Primary Cutaneous B-Cell Lymphoma Occurring at Different Sites or Time Points in the Same Patient** *AMERICAN JOURNAL OF DERMATOPATHOLOGY*  
Fujiwara, M., Morales, A. V., Seo, K., Kim, Y. H., Arber, D. A., Sundram, U. N.  
2013; 35 (1): 11-18
- **Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin** *LEUKEMIA & LYMPHOMA*  
Kim, Y. H., Demierre, M., Kim, E. J., Lerner, A., Rook, A. H., Duvic, M., Robak, T., Samtsov, A., McCulloch, W., Chen, S. C., Waksman, J., Nichols, J., Whittaker, et al  
2013; 54 (2): 284-289
- **Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L., Glenn, M. J., Gockerman, J. P., Gordon, et al  
2012; 10 (12): 1487-1498
- **Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Krahen, M., Sundram, U., Bashey, S., Sutherland, K., Salva, K., Wood, G. S., Advani, R. H., Hoppe, R. T., Reddy, S., Armstrong, R., Nagpal, S., Pulitzer, M., Horwitz, et al  
AMER SOC HEMATOLOGY.2012
- **Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)**  
Duvic, M., Pinter-Brown, L., Foss, F., Sokol, L., Jorgensen, J., Ni, X., Challagundla, P., Goswami, M., Dwyer, K., Mohamed, N., Kim, Y. H.  
AMER SOC HEMATOLOGY.2012
- **Cutaneous gamma delta T-cell Lymphomas A Spectrum of Presentations With Overlap With Other Cytotoxic Lymphomas** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*  
Guitart, J., Weisenburger, D. D., Subtil, A., Kim, E., Wood, G., Duvic, M., Olsen, E., Junkins-Hopkins, J., Rosen, S., Sundram, U., Ivan, D., Selim, M. A., Pincus, et al  
2012; 36 (11): 1656-1665
- **Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels** *75th Annual Meeting of the Society-for-Investigative-Dermatology*  
Bashey, S., Krahen, M., Sutherland, K., Sundram, U., Lingala, B., Horwitz, S., Hoppe, R., Pulitzer, M., Advani, R., Kim, Y.  
NATURE PUBLISHING GROUP.2012: S95–S95

- **Transcriptome sequencing in Sezary Syndrome identifies novel Sezary cell-associated transcripts** *75th Annual Meeting of the Society-for-Investigative-Dermatology*  
Lee, C., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D., Armstrong, R., Weng, W., Aros, C., MAH, A., Kretz, M., Kim, Y. H., Khavari, P. A.  
NATURE PUBLISHING GROUP.2012: S29–S29
- **The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients** *AMERICAN JOURNAL OF HEMATOLOGY*  
Kelly-Sell, M. J., Kim, Y. H., Straus, S., Benoit, B., Harrison, C., Sutherland, K., Armstrong, R., Weng, W., Showe, L. C., Wysocka, M., Rook, A. H.  
2012; 87 (4): 354-360
- **A Comparative Analysis of Cutaneous Marginal Zone Lymphoma and Cutaneous Chronic Lymphocytic Leukemia** *AMERICAN JOURNAL OF DERMATOPATHOLOGY*  
Levin, C., Mirzamani, N., Zwerner, J., Kim, Y., Schwartz, E. J., Sundram, U.  
2012; 34 (1): 18-23
- **Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*  
Mehta, N., Wayne, A. S., Kim, Y. H., Hale, G. A., Alvarado, C. S., Myskowski, P., Jaffe, E. S., Busam, K. J., Pulitzer, M., Zwerner, J., Horwitz, S.  
2012; 12 (1): 20-25
- **Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL**  
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Goolsby, C., Kuzel, T.  
AMER SOC HEMATOLOGY.2011: 712
- **Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome**  
Weng, W., Armstrong, R., Arai, S., Sutherland, K., Hoppe, R. T., Kim, Y. H.  
AMER SOC HEMATOLOGY.2011: 1346
- **Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma**  
Ni, X., Jorgensen, J. L., Goswami, M., Challagundla, P., Decker, W. K., Kim, Y. H., Duvic, M.  
AMER SOC HEMATOLOGY.2011: 204–5
- **EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma** *BLOOD*  
Kempf, W., Pfaltz, K., Vermeer, M. H., Cozzio, A., Ortiz-Romero, P. L., Bagot, M., Olsen, E., Kim, Y. H., Dummer, R., Pimpinelli, N., Whittaker, S., Hodak, E., Cerroni, et al  
2011; 118 (15): 4024-4035
- **A prospective trial of low-dose total skin electron beam therapy in mycosis fungoides and proposal of a new clinically meaningful endpoint**  
Bashey, S., Harrison, C., Navi, D., Lingala, B., Armstrong, R., Weng, W., Sundram, U., Kim, Y., Hoppe, R.  
WILEY-BLACKWELL.2011: 3–3
- **The frequency of dual TCR-PCR clonality in granulomatous disorders** *JOURNAL OF CUTANEOUS PATHOLOGY*  
Dabiri, S., Morales, A., Ma, L., Sundram, U., Kim, Y. H., Arber, D. A., Kim, J.  
2011; 38 (9): 704-709
- **Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma** *LEUKEMIA & LYMPHOMA*  
Querfeld, C., Kuzel, T. M., Kim, Y. H., Porcu, P., Duvic, M., Musiek, A., Rook, A. H., Mark, L. A., Pinter-Brown, L., Hamid, O., Lin, B., Bian, Y., Boye, et al  
2011; 52 (8): 1474-1480
- **Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer** *JOURNAL OF CLINICAL ONCOLOGY*  
Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., Wood, G. S., Willemze, R., Demierre, M., Pimpinelli, N., Bernengo, M. G., Ortiz-Romero, P. L., Bagot, et al  
2011; 29 (18): 2598-2607

- **The Stanford University Experience With Conventional-Dose, Total Skin Electron-Beam Therapy in the Treatment of Generalized Patch or Plaque (T2) and Tumor (T3) Mycosis Fungoides** *ARCHIVES OF DERMATOLOGY*  
Navi, D., Riaz, N., Levin, Y. S., Sullivan, N. C., Kim, Y. H., Hoppe, R. T.  
2011; 147 (5): 561-567
- **Non-Hodgkin's Lymphomas** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., Byrd, J. C., Czuczman, M. S., Fayad, L. E., Glenn, M. J., Gockerman, J. P., Gordon, L. I., Harris, et al  
2011; 9 (5): 484-560
- **Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Olsen, E. A., Rook, A. H., Zic, J., Kim, Y., Porcu, P., Querfeld, C., Wood, G., Demierre, M., Pittelkow, M., Wilson, L. D., Pinter-Brown, L., Advani, R., Parker, et al  
2011; 64 (2): 352-404
- **Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Kim, Y. H., Girardi, M., Duvic, M., Kuzel, T., Link, B. K., Brown, L. P., Rook, A. H.  
2010; 63 (6): 975-983
- **Increased Risk of Second Malignancies In Young Patients with Mycosis Fungoides Diagnosed Before 30 Years of Age: A Population-Based Study**  
Ai, W., Keegan, T., Fish, K., Laura, P., Soon, C., Kim, Y. H., Chang, E.  
AMER SOC HEMATOLOGY.2010: 832
- **Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients**  
Duvic, M., Pinter-Brown, L., Foss, F. M., Sokol, L., Jorgensen, J., Spitalny, G. L., Kim, Y. H.  
AMER SOC HEMATOLOGY.2010: 424
- **Multidisciplinary Care in the Management of Patients With Cutaneous Lymphoma: A Perspective** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*  
Kim, Y. H.  
2010; 10: S106-S108
- **Combined Use of PCR-Based TCRG and TCRB Clonality Tests on Paraffin-Embedded Skin Tissue in the Differential Diagnosis of Mycosis Fungoides and Inflammatory Dermatoses** *JOURNAL OF MOLECULAR DIAGNOSTICS*  
Zhang, B., Beck, A. H., Taube, J. M., Kohler, S., Seo, K., Zwerner, J., Viakhireva, N., Sundram, U., Kim, Y. H., Schrijver, I., Arber, D. A., Zehnder, J. L.  
2010; 12 (3): 320-327
- **Non-Hodgkin's Lymphomas** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., Gordon, L. I., Harris, N. L., Hoppe, et al  
2010; 8 (3): 288-334
- **T-Cell Receptor PCR from Separate Biopsies Distinguishes Granulomatous Dermatitis from Granulomatous Mycosis Fungoides** *99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*  
Dabiri, S., Arber, D. A., Kim, Y. H., Sundram, U. N., Kim, J.  
NATURE PUBLISHING GROUP.2010: 112A-112A
- **Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*  
Kim, Y. H., Demierre, M., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Whittaker, S.  
AMER SOC HEMATOLOGY.2009: 1050-50
- **The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.**  
Duvic, M., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Rizvi, S., Chen, C., Arduino, J., Olsen, E. A.  
AMER SOC HEMATOLOGY.2009: 681

- **Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.**  
Cabell, C., Bates, S., Piekarz, R., Whittaker, S., Kim, Y. H., Currie, M., Godfrey, C. J., Schoonmaker, C., Nichols, J., Nix, D., Burris, H. A.  
AMER SOC HEMATOLOGY.2009: 1428–29
- **Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial**  
Horwitz, S. M., Duvic, M., Kim, Y., Zairi, J. M., Lechowicz, M., Myskowski, P., Fruchtman, S., O'Connor, O. A.  
AMER SOC HEMATOLOGY.2009: 379
- **Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*  
Whittaker, S., Kim, E. J., Prince, M., Demierre, M. F., Giver, C., Lonial, S., Piekarz, R., Kim, Y. H., Nichols, J., Nix, D., Bates, S.  
AMER SOC HEMATOLOGY.2009: 1425–25
- **A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders** *CLINICAL CANCER RESEARCH*  
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., Lorenz, J., Sievers, E. L., Kim, Y. H.  
2009; 15 (19): 6217-6224
- **A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sezary Syndrome** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Wu, P. A., Kim, Y. H., Lavori, P. W., Hoppe, R. T., Stockerl-Goldstein, K. E.  
2009; 15 (8): 982-990
- **Cutaneous Peripheral T-Cell Lymphoma Associated With a Proliferation of B Cells** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*  
Mattoch, I. W., Fulton, R., Kim, Y., Hoppe, R., Warnke, R. A., Sundram, U. N.  
2009; 131 (6): 810-819
- **Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL)** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*  
Demierre, M., Whittaker, S., Kim, Y., Kim, E., Piekarz, R., Prince, M., Nichols, J., Balsler, J., Prentice, A., BATES, S.  
AMER SOC CLINICAL ONCOLOGY.2009
- **Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*  
Weinberg, O. K., Ma, L., Seo, K., Beck, A. H., Pai, R. K., Morales, A., Kim, Y., Sundram, U., Tan, D., Horning, S. J., Hoppe, R. T., Natkunam, Y., Arber, et al  
2009; 33 (4): 591-598
- **Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Cutaneous Involvement A Randomized, Double-Blind, Placebo-Controlled Trial** *ARTHRITIS AND RHEUMATISM*  
Khanna, D., Clements, P. J., Furst, D. E., Korn, J. H., Ellman, M., Rothfield, N., Wigley, F. M., Moreland, L. W., Silver, R., Kim, Y. H., Steen, V. D., Firestein, G. S., Kavanaugh, et al  
2009; 60 (4): 1102–11
- **The morphologic and immunohistochemical overlap between cutaneous marginal zone lymphoma and cutaneous chronic lymphocytic leukemia** *69th Annual Meeting of the Society-of-Investigative-Dermatology*  
Levin, C., Mizramani, N., Zwerner, J., Kim, Y., Sundram, U.  
NATURE PUBLISHING GROUP.2009: S53–S53
- **Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., Kim, Y. H.  
2008; 59 (6): 953-957
- **Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*  
Kim, Y., Whittaker, S., Demierre, M. F., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., Kim, E. J., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Prentice, et al  
AMER SOC HEMATOLOGY.2008: 103–4

- **Cytologic Evaluation of Lymphadenopathy Associated With Mycosis Fungoides and Sezary Syndrome Role of Immunophenotypic and Molecular Ancillary Studies** *CANCER CYTOPATHOLOGY*  
Pai, R. K., Mullins, F. M., Kim, Y. H., Kong, C. S.  
2008; 114 (5): 323-332
- **Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Lee, J., Viakhireva, N., Cesca, C., Lee, P., Kohler, S., Hoppe, R. I., Kim, Y. H.  
2008; 59 (4): 706-712
- **Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates** *AMERICAN JOURNAL OF DERMATOPATHOLOGY*  
Morales, A. V., Arber, D. A., Seo, K., Kohler, S., Kim, Y. H., Sundram, U. N.  
2008; 30 (5): 425-430
- **European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas** *BLOOD*  
Senff, N. J., Noordijk, E. M., Kim, Y. H., Bagot, M., Berti, E., Cerroni, L., Dummer, R., Duvic, M., Hoppe, R. T., Pimpinelli, N., Rosen, S. T., Vermeer, M. H., Whittaker, et al  
2008; 112 (5): 1600-1609
- **Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma** *MODERN PATHOLOGY*  
Xie, X., Sundram, U., Natkunam, Y., Kohler, S., Hoppe, R. T., Kim, Y. H., Cook, J. R., Hammel, J., Swerdlow, S. H., Guitart, J., Smith, M. D., Bosler, D., Listinsky, et al  
2008; 21 (6): 653-659
- **International trial confirms romidpesin efficacy in refractory CTCL patients** *10th International Conference on Malignant Lymphoma*  
Prentice, A., Whittaker, S., Kim, Y., Kim, E., LERNER, A., Duvic, M., Robak, T., Baran, E., Becker, J., McCulloch, W.  
OXFORD UNIV PRESS.2008: 116-116
- **An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML** *BLOOD*  
Bullinger, L., Doehner, K., Kranz, R., Stirner, C., Froeling, S., Scholl, C., Kim, Y. H., Schlenk, R. F., Tibshirani, R., Doehner, H., Pollack, J. R.  
2008; 111 (9): 4490-4495
- **Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.** *Journal of the National Comprehensive Cancer Network*  
Horwitz, S. M., Olsen, E. A., Duvic, M., Porcu, P., Kim, Y. H.  
2008; 6 (4): 436-442
- **Radiation therapy is an effective treatment for refractory Woringer-Kolopp disease** *International Investigative Dermatology Meeting*  
Lee, I. L., Viakhireva, N., Cesca, C., Lee, P., Kohler, S., Hoppe, R., Kim, Y.  
NATURE PUBLISHING GROUP.2008: S70-S70
- **Romidepsin has activity in refractory ctcl: an international multicenter study** *International Investigative Dermatology Meeting*  
Whittaker, S., Scarisbrick, J., Kim, Y., Reddy, S., Kim, E., Rook, A., LERNER, A., Demierre, M., Duvic, M., Robak, T., Baran, E., Becker, J., Samtsov, et al  
NATURE PUBLISHING GROUP.2008: S74-S74
- **Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome** *49th Annual Meeting of the American-Society-of-Hematology*  
Woo, D., Jones, C., Vanoli-Storz, M., Kohler, S., Reddy, S., Advani, R., Hoppe, R., Kim, Y.  
AMER SOC HEMATOLOGY.2007: 1045A-1045A
- **Response to oral forodesine in refractory cutaneous T-Cell lymphoma: Interim results of a phase I/II study**  
Duvic, M., Forero-Torres, A., Foss, F., Olsen, E., Kim, Y.  
AMER SOC HEMATOLOGY.2007: 44A
- **Combined BIOMED-2 clonality assays for IGH and IGK and assessment of t(14;18) on formalin-fixed, paraffin embedded tissues effectively separates primary cutaneous B cell lymphomas from reactive cutaneous lymphoid hyperplasia.**  
Morales, A. V., Seo, K., Arber, D. A., Kohler, S., Kim, Y. H., Sundram, U.

AMER SOC HEMATOLOGY.2007: 772A-773A

- **Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study** *49th Annual Meeting of the American-Society-of-Hematology*  
Advani, R., Hymes, K., Pohlman, B., Jacobsen, E., McDonnell, J., Belt, R., LERNER, A., Kim, Y., MUNDIS, R., MANSFIELD, T., Buhl-Jensen, P., Ooi, C. E., Duvic, et al  
AMER SOC HEMATOLOGY.2007: 1012A-1012A
- **Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: An International, Multicenter study** *49th Annual Meeting of the American-Society-of-Hematology*  
Kim, Y. H., Reddy, S., Kim, E. J., Rook, A. H., Lerner, A., Demierre, M., Duvic, M., Whittaker, S., Robak, T., Becker, J. C., McCulloch, W., Prentice, A. G.  
AMER SOC HEMATOLOGY.2007: 44A-44A
- **T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides** *43rd Annual Meeting of the American-Society-of-Dermatopathology*  
Thurber, S. E., Zhang, B., Kim, Y. H., Schrijver, I., Zehnder, J., Kohler, S.  
MOSBY-ELSEVIER.2007: 782-90
- **Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)** *BLOOD*  
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., Wood, G., Dummer, R., Ranki, et al  
2007; 110 (6): 1713-1722
- **Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis** *ARCHIVES OF DERMATOLOGY*  
Richmond, H., Zwerner, J., Kim, Y., Fiorentino, D.  
2007; 143 (8): 1025-1030
- **Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma** *48th Annual Meeting of the American-Society-of-Hematology*  
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., Duvic, M.  
AMER SOC CLINICAL ONCOLOGY.2007: 3109-15
- **Out on a limb: prognostic factors in primary cutaneous anaplastic large cell lymphoma** *68th Annual Meeting of the Society-for-Investigative-Dermatology*  
Jones, C. R., Kohler, S., Cobb, K., Friedman, G. D., Reddy, S., Adrani, R., Hoppe, R., Kim, Y.  
NATURE PUBLISHING GROUP.2007: S62-S62
- **Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome - Evidence from population-based and clinical cohorts** *ARCHIVES OF DERMATOLOGY*  
Huang, K. P., Weinstock, M. A., Clarke, C. A., McMillan, A., Hoppe, R. T., Kim, Y. H.  
2007; 143 (1): 45-50
- **Preliminary report on a phase I/II study of intratumoral injection of PF-3512676 (CpG 7909), a TLR9 agonist, combined with radiation in recurrent low-grade lymphomas.** *48th Annual Meeting of the American-Society-of-Hematology*  
Ai, W. Y., Kim, Y., Hoppe, R. T., Shah, S., Horning, S. J., Tibshirani, R., Levy, R.  
AMER SOC HEMATOLOGY.2006: 767A-768A
- **Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial.**  
Duvic, M., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J., Randolph, S., Richon, V. M., Olsen, et al  
AMER SOC HEMATOLOGY.2006: 122A
- **Phase II preliminary results of SGN-30 (anti-CD30 mAb) in patients with CD30+lymphoproliferative disorders.** *48th Annual Meeting of the American-Society-of-Hematology*  
Duvic, M., Kim, Y., Reddy, S., Forero-Torres, A., Pinter-Brown, L. C., Rarick, M. U., Zic, J., Worobec, S., Korman, N., Kuzel, T., Bohjanen, K., Flessland, K., Barton, et al  
AMER SOC HEMATOLOGY.2006: 773A-773A

- **Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial.**  
Duvic, M., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J., Randolph, S., Richon, V. M., Olsen, et al  
AMER SOC HEMATOLOGY.2006: 122A
- **Phase II preliminary results of SGN-30 (anti-CD30 mAb) in patients with CD30+lymphoproliferative disorders.** *48th Annual Meeting of the American-Society-of-Hematology*  
Duvic, M., Kim, Y., Reddy, S., Forero-Torres, A., Pinter-Brown, L. C., Rarick, M. U., Zic, J., Worobec, S., Korman, N., Kuzel, T., Bohjanen, K., Flessland, K., Barton, et al  
AMER SOC HEMATOLOGY.2006: 773A–773A
- **Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology** *JOURNAL OF CUTANEOUS PATHOLOGY*  
Jayaraman, A. G., Cassarino, D., Advani, R., Kim, Y. H., Tsai, E., Kohler, S.  
2006; 33: 6-11
- **Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography** *65th Annual Meeting of the Society-for-Investigative-Dermatology*  
Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., Dick, S., Chow, S., Advani, R., Warnke, R., Kohler, S., Hoppe, R. T., Kim, Y. H.  
AMER MEDICAL ASSOC.2006: 577–84
- **A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Knobler, R. M., French, L. E., Kim, Y., Bisaccia, E., Graninger, W., Nahavandi, H., Strobl, F. J., Keystone, E., Mehlmauer, M., Rook, A. H., Braverman, Systemic Sclerosis Study Grp  
2006; 54 (5): 793–99
- **Phase II preliminary results suggest SGN-30 (Anti-CD30 monoclonal antibody) is active and well-tolerated in patients with cutaneous anaplastic large cell lymphoma** *67th Annual Meeting of the Society-for-Investigative-Dermatology*  
Duvic, M., Kunishige, J., Kim, Y., Reddy, S., Forero-Torres, A., Pinter-Brown, L., Rarick, M., Zic, J., Worobec, S., Flessland, K., Barton, J.  
NATURE PUBLISHING GROUP.2006: 45–45
- **Superior clinical outcome for patients receiving allogeneic over autologous stem cell transplant in mycosis fungoides and Sezary syndrome** *67th Annual Meeting of the Society-for-Investigative-Dermatology*  
Wu, P. A., Stockerl-Goldstein, K., Reddy, S. A., Hoppe, R. T., Kim, Y. H.  
NATURE PUBLISHING GROUP.2006: 40–40
- **The Stanford experience with utilizing the new WHO classification of cutaneous lymphomas for cutaneous B cell lymphoma** *67th Annual Meeting of the Society-for-Investigative-Dermatology*  
Reddy, S., Kohler, S., Horwitz, S., Sutherland, K., Hoppe, R. T., Kim, Y. H.  
NATURE PUBLISHING GROUP.2006: 44–44
- **Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma.** *47th Annual Meeting of the American-Society-of-Hematology*  
Molina, A. M., Advani, R., Reddy, S., Hoppe, R., Friedberg, J. W., Sadan, S., Myskowski, P., Kim, Y. H., Horwitz, S. M.  
AMER SOC HEMATOLOGY.2005: 934A–934A
- **Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study** *JOURNAL OF CUTANEOUS PATHOLOGY*  
Sundram, U., Kim, Y., Mraz-Gernhard, S., Hoppe, R., Natkunam, Y., Kohler, S.  
2005; 32 (3): 227-234
- **Primary cutaneous CD30+ anaplastic large cell lymphoma: Analysis of the Stanford series reveals two clinical subsets of patients.** *46th Annual Meeting of the American-Society-of-Hematology*  
Reddy, S. A., Liu, H., Kohler, S., Hoppe, R. T., Kim, Y. H.  
AMER SOC HEMATOLOGY.2004: 226B–226B
- **Marked improvement in staging accuracy in mycosis fungoides/Sezary syndrome using integrated positron emission tomography and computed tomography (PET/CT)**  
Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Dick, S. E., Chow, S., Advani, R., Warnke, R. A., Kohler, S., Hoppe, R. T., Kim, Y. H.

AMER SOC HEMATOLOGY.2004: 854A–855A

- **Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients** *ARCHIVES OF DERMATOLOGY*  
Beynet, D. P., Wee, S. A., Horwitz, S. S., Kohler, S., Horning, S., Hoppe, R., Kim, Y. H.  
2004; 140 (9): 1140-1146
- **CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., Kim, Y. H.  
2003; 49 (6): 1049-1058
- **HuMax-CD4, a fully human monoclonal antibody: Early results of an ongoing phase II trial in cutaneous T cell lymphoma**  
Obitz, E., Kim, Y. H., Iversen, L., Osterborg, A., Jensen, P., Baadsgaard, O., Knox, S. J.  
AMER SOC HEMATOLOGY.2003: 645A
- **Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression** *63rd Annual Meeting of the Society-for-Investigative-Dermatology*  
Kim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A., Hoppe, R. T.  
AMER MEDICAL ASSOC.2003: 857–66
- **Gene expression profiles of cutaneous B cell lymphoma** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*  
Storz, M. N., van de Rijn, M., Kim, Y. H., Mraz-Gernhard, S., Hoppe, R. T., Kohler, S.  
2003; 120 (5): 865-870
- **Topical nitrogen mustard in the management of mycosis fungoides - Update of the Stanford experience** *ARCHIVES OF DERMATOLOGY*  
Kim, Y. H., Martinez, G., Varghese, A., Hoppe, R. T.  
2003; 139 (2): 165-173
- **Management with topical nitrogen mustard in mycosis fungoides.** *Dermatologic therapy*  
Kim, Y. H.  
2003; 16 (4): 288-298
- **The largest single-center US study of cutaneous CD30+lymphoproliferative disorders**  
Liu, H., Kohler, S., Harvell, J., Hoppe, R., Kim, Y.  
NATURE PUBLISHING GROUP.2002: 237–37
- **Clinical and pathological spectrum of post-transplant lymphoproliferative disorders with skin involvement**  
Wee, S., Horowitz, S., Kohler, S., Kim, Y. H.  
NATURE PUBLISHING GROUP.2002: 243–43
- **Management with topical nitrogen mustard in mycosis fungoides: Update of the Stanford experience**  
Kim, Y. H., Hoppe, R. T.  
NATURE PUBLISHING GROUP.2002: 234–34
- **Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK (R))** *CLINICAL LYMPHOMA*  
Duvic, M., Kuzel, T., Olsen, E. A., Martin, A. G., Foss, F. M., Kim, Y. H., Heald, P. W., Bacha, P., Nichols, J., Liepa, A.  
2002; 2 (4): 222-228
- **Bexarotene gel - A food and drug administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma** *ARCHIVES OF DERMATOLOGY*  
Liu, H. L., Kim, Y. H.  
2002; 138 (3): 398–99
- **Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morphea** *JOURNAL OF CUTANEOUS PATHOLOGY*  
Su, L. D., Kim, Y. H., LeBoit, P. E., Swetter, S. M., Kohler, S.  
2002; 29 (3): 135-141
- **Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases** *JOURNAL OF CUTANEOUS PATHOLOGY*  
Harvell, J. D., Vaseghi, M., Natkunam, Y., Kohler, S., Kim, Y.

2002; 29 (2): 88-92

- **Natural killer/natural killer-like T-Cell lymphoma, CD56+, presenting in the skin: An increasingly recognized entity with an aggressive course** *JOURNAL OF CLINICAL ONCOLOGY*  
Mraz-Gernhard, S., Natkunam, Y., Hoppe, R. T., Leboit, P., Kohler, S., Kim, Y. H.  
2001; 19 (8): 2179-2188
- **Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides** *JOURNAL OF CLINICAL ONCOLOGY*  
de Coninck, E. C., Kim, Y. H., Varghese, A., Hoppe, R. T.  
2001; 19 (3): 779-784
- **Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*  
Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, et al  
2001; 19 (2): 376-388
- **Natural killer/natural killer-like T-cell lymphoma (CD56+) presenting in the skin: A study of clinical and pathologic characteristics affecting survival.**  
Mraz-Gernhard, S. M., Hoppe, R. T., Natkunam, Y., Leboit, P., Kohler, S., Kim, Y. H.  
AMER SOC HEMATOLOGY.2000: 124A-125A
- **The clinical spectrum of cutaneous B-cell lymphomas (CBCL): Excellent prognosis for patients with disease limited to the skin.**  
Mraz-Gernhard, S. M., Horwitz, S., Kim, Y. H., Kohler, S., Hoppe, R.  
AMER SOC HEMATOLOGY.2000: 329A
- **Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases** *JOURNAL OF CUTANEOUS PATHOLOGY*  
Natkunam, Y., Warnke, R. A., Haghighi, B., Su, L. D., Le Boit, P. E., Kim, Y. H., Kohler, S.  
2000; 27 (8): 392-399
- **Oral bexarotene is safe and effective in a phase II-III clinical trial in refractory or persistent early stage CTCL.**  
Duvic, M., Martin, A., Kim, Y., Olsen, E., Wood, G., Yocum, R.  
AMER SOC HEMATOLOGY.1999: 659A
- **Epidermotropic cutaneous B-cell lymphoma mimicking mycosis fungoides** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Chui, C. T., Hoppe, R. T., Kohler, S., Kim, Y. H.  
1999; 41 (2): 271-274
- **Mycosis fungoides and the Sezary syndrome** *SEMINARS IN ONCOLOGY*  
Kim, Y. H., Hoppe, R. T.  
1999; 26 (3): 276-289
- **Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides** *40th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology*  
Chinn, D. M., Chow, S., Kim, Y. H., Hoppe, R. T.  
ELSEVIER SCIENCE INC.1999: 951-58
- **Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides** *ARCHIVES OF DERMATOLOGY*  
Kim, Y. H., Chow, S., Varghese, A., Hoppe, R. T.  
1999; 135 (1): 26-32
- **Role of histology in providing prognostic information in mycosis fungoides** *JOURNAL OF CUTANEOUS PATHOLOGY*  
SMOLLER, B. R., Detwiler, S. P., Kohler, S., Hoppe, R. T., Kim, Y. H.  
1998; 25 (6): 311-315
- **Mycosis fungoides in young patients: Clinical characteristics and outcome** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Crowley, J. J., Nikko, A., Varghese, A., Hoppe, R. T., Kim, Y. H.  
1998; 38 (5): 696-701

- **Changes in quality of life (QOL) for patients (pts) enrolled in a phase III trial of treatment with a diphtheria toxin fusion protein (DAB(389)IL-2) for mycosis fungoides (MF).**  
Liepa, A., Bennett, C. L., Yarnold, P. R., Enas, N., Lozano, J., Kuzel, T., Olson, E., Martin, A., Kim, Y., Duvic, M., Frankel, A., Vonderheid, E., Bowen, et al  
AMER SOC HEMATOLOGY.1997: 3924-24
- **Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: A critical reappraisal** *33rd Annual Meeting of the American-Society-of-Dermatopathology*  
Kohler, S., Kim, Y. H., SMOLLER, B. R.  
MUNKSGAARD INT PUBL LTD.1997: 292-97
- **Blastomycosis-like pyoderma in a man with AIDS** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Crowley, J. J., Kim, Y. H.  
1997; 36 (4): 633-634
- **Clinical stage IA (limited patch and plaque) mycosis fungoides - A long-term outcome analysis** *ARCHIVES OF DERMATOLOGY*  
Kim, Y. H., Jensen, R. A., WATANABE, G. L., Varghese, A., Hoppe, R. T.  
1996; 132 (11): 1309-1313
- **Evidence against a role for human T-cell lymphotropic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*  
Wood, G. S., Salvekar, A., Schaffer, J., CROOKS, C. F., HENGHOLD, W., Fivenson, D. P., Kim, Y. H., SMOLLER, B. R.  
1996; 107 (3): 301-307
- **Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30(+) primary cutaneous lymphoproliferative disorders and Hodgkin's disease** *BLOOD*  
Wood, G. S., Hardman, D. L., Boni, R., Dummer, R., Kim, Y. H., SMOLLER, B. R., Takeshita, M., Kikuchi, M., Burg, G.  
1996; 88 (5): 1765-1770
- **REASSESSMENT OF HISTOLOGIC PARAMETERS IN THE DIAGNOSIS OF MYCOSIS-FUNGOIDES** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*  
SMOLLER, B. R., Bishop, K., Glusac, E., Kim, Y. H., Hendrickson, M.  
1995; 19 (12): 1423-1430
- **CUTANEOUS GNATHOSTOMIASIS** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Crowley, J. J., Kim, Y. H.  
1995; 33 (5): 825-828
- **PROGNOSTIC FACTORS IN ERYTHRODERMIC MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME** *ARCHIVES OF DERMATOLOGY*  
Kim, Y. H., Bishop, K., Varghese, A., Hoppe, R. T.  
1995; 131 (9): 1003-1008
- **LYMPHOCYTE ANTIGEN ABNORMALITIES IN INFLAMMATORY DERMATOSES** *APPLIED IMMUNOHISTOCHEMISTRY*  
SMOLLER, B. R., Bishop, K., Glusac, E. J., Bhargava, V., Kim, Y. H., Warnke, R. A.  
1995; 3 (2): 127-131
- **JUNCTIONAL EPIDERMOLYSIS-BULLOSA SKIN GRAFTED TO THE SCID MOUSE SHOWS PRESERVATION OF THE DISEASE PHENOTYPE**  
MARINKOVICH, M. P., WOODLEY, D. T., WATANABE, G. L., JENSEN, R. A., CANTRELL, C. F., BANER, E. A., HOEFFLER, W. K., KIM, Y. H.  
BLACKWELL SCIENCE PUBL INC CAMBRIDGE.1995: 603
- **PHENOTYPIC REVERSION OF JUNCTIONAL EPIDERMOLYSIS-BULLOSA KERATINOCYTES BY THE INTRODUCTION OF A THERAPEUTIC LAMININ-5 CHAIN GENE**  
HOEFFLER, W. K., WANG, C. K., MATSUI, C., CANTRELL, C. F., GERECKE, D., KIM, Y., HERRON, G. S., BAUER, E. A.  
BLACKWELL SCIENCE PUBL INC CAMBRIDGE.1995: 597
- **REASSESSMENT OF LYMPHOCYTE IMMUNOPHENOTYPING IN THE DIAGNOSIS OF PATCH AND PLAQUE STAGE LESIONS OF MYCOSIS-FUNGOIDES** *APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY*  
SMOLLER, B. R., Bishop, K., Glusac, E. J., Kim, Y. H., Bhargava, V., Warnke, R. A.  
1995; 3 (1): 32-36

- **CONSTITUTIVE ACTIVATION OF THE COLLAGENASE PROMOTER IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA FIBROBLASTS - ROLE OF ENDOGENOUSLY ACTIVATED AP-1** *EXPERIMENTAL CELL RESEARCH*  
Unemori, E. N., Mauch, C., Hoeffler, W., Kim, Y., Amento, E. P., BAUER, E. A.  
1994; 211 (2): 212-218
- **DETERMINATION OF HUMAN PAPILLOMA-VIRUS IN NON-ANOGENITAL SQUAMOUS-CELL CARCINOMAS BY POLYMERASE CHAIN-REACTION**  
KIM, Y. H., SERKLAND, L. F., BAUER, E. A., PALEFSKY, J. M.  
BLACKWELL SCIENCE INC.1994: 652
- **Autoimmunity to anchoring fibrils.** *Advances in dermatology*  
Kim, Y. H., Woodley, D. T.  
1994; 9: 61-77
- **RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA KERATINOCYTES SYNTHESIZE TYPE-VII COLLAGEN ALPHA-CHAINS OF NORMAL MOLECULAR-SIZE BUT THE ANCHORING FIBRIL ASSEMBLY IS IMPAIRED** *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*  
IWASAKI, T., LAPIERE, J. C., UITTO, J., KIM, Y. H., WOODLEY, D. T.  
1993; 193 (2): 604–10
- **BIOLOGIC CHARACTERISTICS OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES**  
Kim, Y. H., Kim, J. P., Chen, J. D., Iwasaki, T., Hernandez, G., SARAF, P., BAUER, E. A., Woodley, D. T.  
NATURE PUBLISHING GROUP.1993: 580–80
- **RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES SYNTHESIZE TYPE-VII (ANCHORING FIBRIL) COLLAGEN ALPHA-CHAINS OF NORMAL MOLECULAR-SIZE**  
IWASAKI, T., LAPIERE, J. C., UITTO, J., KIM, Y. H., WOODLEY, D. T.  
BLACKWELL SCIENCE INC.1993: 515
- **JUNCTIONAL EPIDERMOLYSIS-BULLOSA (JEB) KERATINOCYTES FAIL TO SECRETE HEMIDESMOSOME (HD)-ASSOCIATED MATRIX-ELEMENTS AND DEMONSTRATE ENHANCED LOCOMOTION**  
Chen, J. D., LANGHOFER, M., Iwasaki, T., Kim, Y. H., Jones, J. C., Krueger, J. G., Carter, D. M., Woodley, D. T.  
NATURE PUBLISHING GROUP.1993: 517–17
- **JUNCTIONAL EPIDERMOLYSIS-BULLOSA (JEB) KERATINOCYTES FAIL TO SECRETE HEMIDESMOSOME (HD)-ASSOCIATED MATRIX-ELEMENTS AND DEMONSTRATE ENHANCED LOCOMOTION**  
Chen, J. D., LANGHOFER, M., Iwasaki, T., Kim, Y. H., Jones, J. C., Krueger, J. G., Carter, D. M., Woodley, D. T.  
SLACK INC.1993: A408–A408
- **BIOLOGIC CHARACTERISTICS OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES**  
Kim, Y. H., Kim, J. P., Chen, J. D., Iwasaki, T., Hernandez, G., SARAF, P., BAUER, E. A., Woodley, D. T.  
SLACK INC.1993: A479–A479
- **A DOUBLE-BLIND COMPARISON OF ADHESIVE BANDAGES WITH THE USE OF UNIFORM SUCTION BLISTER WOUNDS** *ARCHIVES OF DERMATOLOGY*  
Woodley, D. T., Kim, Y. H.  
1992; 128 (10): 1354-1357
- **RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA PHENOTYPE IS PRESERVED IN XENOGRAFTS USING SCID MICE - DEVELOPMENT OF AN EXPERIMENTAL INVIVO MODEL** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*  
Kim, Y. H., Woodley, D. T., WYNN, K. C., GIOMI, W., BAUER, E. A.  
1992; 98 (2): 191-197
- **H-1-NMR SPECTROSCOPY - AN APPROACH TO EVALUATION OF DISEASED SKIN INVIVO** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*  
Kim, Y. H., Orenberg, E. K., Faull, K. F., WADEJARDETZKY, N. G., Jardetzky, O.  
1989; 92 (2): 210-216
- **High-throughput Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Reveals Candidate Pathogenic Mutations.** *Applied immunohistochemistry & molecular morphology : AIMM*  
Fernandez-Pol, S. n., Costa, H. A., Steiner, D. F., Ma, L. n., Merker, J. D., Kim, Y. H., Arber, D. A., Kim, J. n.  
; 27 (10): 740–48